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ABSTRACT 
Angiogenesis, the formation of new capillaries from pre-existing vessels, is essential for 
tumor progression. It is critical for the growth of primary cancers. In this thesis, we present a 
new approach to angiogenesis, based on the theory of reinforced random walks, coupled with 
a Michaelis-Menten type mechanism. This views the endothelial cell receptors as the catalyst 
for transforming angiogenic factor into proteolytic enzyme in order to model the first stage. In 
our model we use a curvature-induced proliferation term for the endothelial cell equation. Our 
numerical results indicate that the proliferation of endothelial cells is high at the tip. .A,lso, we 
observe that the tip movement speeds up as it gets close to the tumor. 
•A. coupled system of ordinary and partial differential equations is derived which, in the pres­
ence of an angiogenic agent, predicts the aggregation of the endothelial cells and the collapse of 
the vascular lamina, opening a passage into the e.xtracellular matrix (ECM). We have dynam­
ical equations not only in a two-dimensional region,the ECM, but also in a one-dimensional 
region, the capillary. We also consider the effect of the angiostatin on the endothelial cell 
proliferation and fibronectin. 
Our computations are compared with the results of Judah Folkman's classical rabbit eye 
experiments in which he demonstrated that tumors can produce angiogenic growth factors. 
Using only classical enzyme kinetics and reinforced random walk cell transport equations, we 
are able to "predict" how long it should take for a new capillary to grow from the limbus 
of the rabbit eye to an implanted malignancy. The "predictions" agree very well with the 
experiments. 
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1 
INTRODUCTION 
Angiogenesis. the formation of new capillaries from pre-existing vessels, is essential for 
tumor progression. Furthermore, it is critical for the growth of primary cancers. 
Solid tumors progress through essentially two distinct phases of growth, namely the avas­
cular phase and the vascular phase. In the avascular phase, the tumor does not have its own 
blood supply. .A.t this stage it is 2-3 mm in diameter and grows by feeding on nutrients in the 
e.xtra cellular matrix (ECM), which are supplied to it via diffusion. 
In the vascular phase, the tumor has its own blood supply and rapidly grows. Folkman 
k. Shing (1992) showed that the tumor releases certain chemicals known as tumor angiogen­
esis factors (TAFs). This stimulates the endothelial cells (ECs) in neighboring capillaries to 
migrate toward the tumor. Capillaries, proliferating in response to a tumor implant, elongate 
by the same mechanisms as wound-induced vessels: mitosis of endothelial cells accompanied 
by migration of these cells toward the angiogenic stimulus. [4]. This process culminates in 
the formation of an e.xtensive dendritic structure of new capillaries which exhibit extensive 
anastomosis and branching. This complex network will eventually penetrate the tumor and 
furnish it with the blood supply it requires for continued growth and metastatis to occur. (See 
Figure 1.1, below which is taken from [15].) 
Angiogenesis is known to occur in three sequential steps. [33]. First, the endothelial cells 
lining the vascular basal lamina ("basement membrane") degrade this membrane. Second, the 
endothelial ceils migrate and proliferate (via mitosis) into the ECM. Finally, capillary loops 
may form. In recent years, progress has been made to understand this phenomenon at the 
molecular level. This includes the identification of potent angiogenic factors, the discovery 
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Figure 1.1 Diagram of different targets for antiangiogenic therapy. [15]. 
i (• 
U! 
of the role of proteases, the importance of the (ECM), and the emerging characterization 
of signal transduction pathways in endothelial cells. 
The T.A.F's stimulate the EC's to produce a substance called plasminogen activator (PA), 
The (RA.), in its turn, converts the plasminogen to a proteolytic enzyme, plasmin, which 
degrades the basement lamina and the ECM. See Figures 1.2, 1.3, 1.4, 1.5 below, which are 
taken from [34]. 
.A. survey of the Uterature shows that over fifty putative factors may be involved in angio-
genesis. Effects vary depending on the environment and the concentration of these substances, 
with different results often obtained under m vivo and m uitro experimental conditions. The 
most often cited angiogenic peptides which are effective both m tnvo and m mtro are vascular 
endothelial growth factor, platelet-derived endothelial growth factor (PD-ECGF), transforming 
growth factor, 0 , (TGF/3) and tumor necrosis factor, a, (TNFa). 
3 
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Figure 1.2 Normal capillary. [34]. 
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Figure L.3 Onset of angiogenesis. [34]. 
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Figure 1.5 Notice the anastomosis (capillary loop). [34]. 
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In addition to the angiogenic factors above, vascular growth can be futher modified and 
regulated by local geometric conditions: endothelial size and shape and the location of other 
cell types such as smooth muscle cells, pericytes, platelets, macrophages and mast cells. [34]. 
EC must interact with the ECM during the growth of new vessels toward an angiogenic 
stimulus. The ECM is the barrier that the EC must penetrate in order to achive vasculariza­
tion. Consisting of interstitial tissue, collagen fibre, fibronectin fibrils and fibronectin, as well as 
other components, the ECM is fibrous, so it can guide the growth of capillary sprouts. [1]. En­
dothelial cells lining the blood vessels rest on a basement membrane, the capillary wall. During 
the course of angiogenesis, endothelial cells penetrate this basement membrane and continue 
to migrate and proliferate as cords of cells in the perivascular tissue stroma. Endothelial cell 
migration and proliferation also occur during endothelial repair in situ; the ability to penetrate 
the vascular basement membrane, on the other hand, is an aspect of endothelial cell behavior 
uniquely e.xpressed during angiogenesis. [35]. One of the major components of the ECM is 
fibronectin, a large, highly adhesive glycoprotein particularly abundant in plasma, connective 
tissue matrices, and basement membranes. [27]. Fibronectin is also known to enhance EC 
adhesion to collagen and is produced by ECs. 
Fibronectin is thought to be involved in a wide variety of cellular activities. The simplest 
unifjdng interpretation of these findings is that the fibronectin functions as adhesive proteins 
that bind cells to other cells or to substrata. Fibronectin-treated cells also migrate more 
rapidly, both as single cells or as masses of cells migrating out from cell aggregates. [43]. 
Chemotaxis is the vectorial migration of cells in the direction of gradient in a chemical 
stimulus. In their study of the chemota.xis of aortic endothelial cells in response to fibronectin, 
Bowersox & Sorgente (1982) were interested in determining if fibronectin could act as a stimulus 
for events necessary for new blood vessel growth. They found that variability in the chemotactic 
response was greatest at lower fibronectin concentrations and that when no fibronectin gradient 
was present, cell migration was no greater than background levels. As long as a concentration 
gradient of fibronectin existed, chemotaxis was observed. 
In Chapter 2, we introduce a mathematical model for tumor-induced angiogenesis in the 
6 
ECM. In Chapter 3, we present a mathematical analysis of the model. In Chapter 4, we 
estimate the parameter values used in the model along with numerical experiments. In Chapter 
5, we present our main conclusion. In chapter 6, we present the numerical simulations. A TAF 
induced aggregation of endothelial cells at certain sites on the inside of the vessel wall develops, 
which in turn induces an increase in the endothelial cell concentration in the ECM just outside 
of the vessel. Eventually, endothelial cells migrate across the ECM and reach the tumor wall. 
Anti-angiogenic factors are an issue which we also consider in our model. These factors 
are important in wound healing and for inhibiting tumor growth by prevention of the onset 
of vascularization. Malignant tumors do not grow without inducing a new vessel formation. 
They are angiogenesis-dependent diseases. The hypothesis of Dr.Folkman in 1971-that tumor 
growth is angiogenesis dependent is now accepted. The question now becomes, "Is it possible 
to treat cancer by attacking its blood supply?" Many researchers have directed their research 
to anti-angiogenic therapy. .Although much is known about tumor-induced angiogenesis, the 
mechanism as to how anti-angiogenic agents inhibit new vessel formation remains incompletely 
understood. Even the mechanisms of two of the most potent preclinical anti-angiogenic drugs, 
angiostatin and endostatin, are still unknown. [44]. 
At present, patients diagnosed with any form of cancer typically rely on surgery or radiation 
to remove or eradicate the original tumor and on follow-up radiation, chemotherapy, or both 
to try to eliminate any remaining cancerous cells in the body. Antiangiogenic therapy, in 
contrast to many other therapeutic approaches, does not aim to destroy tumors. Instead, 
by limiting their blood supply, it attempts to shrink tumors and prevent them from growing. 
Anti-angiogenic drugs stop new vessels from forming around a tumor and break up the e.Kisting 
network of abnormal capillaries that feeds the cancerous mass. (See Figure 1.6 taken from 
[16].). In our model we consider the effect of angiostatin, an inhibitor of angiogenesis that 
is known to reduce endothelial cell proliferation and consequently prevent the progression of 
tumor metastases. Moreover, our numerical results agree with the above ideas. 
Endothdiai ceils In 
the ufsilljry rdease 
protein growth factors 
Capillaries proilfierale; 
tumor begins to grow IN SITU TUMOR 
Tumor cdls release 
angiogenic proteins and 
suppress levels of 
angiogenesis Inhibitors 
Tumor continues to 
expand, eventually spreadng 
to other orgarv 
After treatment with 
antlangiogenic c^gs, 
tumor dminishes In size 
Figure 1.6 Fighting Cancer by Attacking Its Blood Supply. [16] 
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2 
MATHEMATICAL MODELS 
In our model we will use the idea of reinforced random walks introduced by Davis (1990). 
0thmer & Stevens (1997) used this idea to describe the movement of living organisms. In 
particular, they studied the micro bacteria myxococus fulvius and myxamoebea dictyostelium 
discoidium. They also derived a system of equations which may exhibit finite-time blow up 
of solutions, collapse or aggregation. In [24], the authors gave a detailed analysis, along with 
numerical simulations, showing the e.Kistence of solutions which exhibit finite-time blow up, 
collapse or aggregation. In the following section, we study the en2yme kinetics we use in our 
model. In the subsequent section, we apply the idea of random walk discussed above. 
2.1 Enzyme kinetics 
In order to see how the angiogenic growth factor acts on endothelial cells, we use the idea 
that each cell has receptor proteins which bind to the growth factor. The resultant complex 
breaks down in the cell interior to form protease and a receptor of the same type as the original. 
In [22] SC [23], the authors used the following idea to model this process: 
Let V be the angiogenic growth factor produced by the tumor and RE be some receptor site on 
the EC wall. [RGV] is an intermediate complex and C is the proteolytic enzyme produced by 
this reaction. Ca, active enzyme, is part of the proteolytic enzyme which actually breaks down 
the fibronectin. The third equation in (2.1) shows that Ca acts as a catalyst to convert the 
fibronectin into products F'. REA is a receptor on the endothelial cell wall and [AREA\ is the 
intermediate complex. la is a protease inhibitor produced by ECs in response to angiostatin 
by a mechanism which is of Michealis-Menten type. (See Figure 2.1 for schematic explanation 
9 
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Figure 2.1 Michealis-Menten Kinetics 
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of Michealis-Menten Kinetics). Here C,-, the inactive fraction of enzyme, represents the 
concentration of proteolytic enzyme molecules that are inhibited by the inhibitor la from 
functioning as a catalyst for fibronectin degradation. In terms of concentrations, [C] = [CJ + 
[C,]. Assuming that the last step in (2.1) is in equilibrium, we have that [C,] = i^e[U][Ca.] where 
£/e is the equilibrium constant. Symbolically, 
V + Re ^ 
fc_l 
ReV 
ReV ^ C ^ R e  
F + Ca ^ C^F 
C^F ^ F' + Ca (2.1) 
.4 + Rea — ••i-REA 
•'^Rea -4  ^ IA + REA 
Co. 4" /a — Ci. 
The kis are called reaction rates in the application of the Law of Mass Action, which asserts 
that the rate of a reaction is proportional to the product of the concentrations of the reactants. 
All of the concentrations below are expressed in micromoles / L = nM. We introduce the 
following notation: 
[iV] = concentration of endothelial cells 
[V^ = concentration of angiogenic factor 
[C] = concentration of proteolytic enzyme 
[F] = concentration of fibronectin 
11 
[.4] = concentration of angiostatin 
[/a] = concentration of protease inhibitor 
[Ca] = concentration of active proteolytic enzyme 
[C,] = concentration of inhibited proteolytic enzyme 
[/?£;] = concentration of angiogenic response receptors, Re , on the EC 
= concentration of angiostatin receptors, Rea^ oti the EC 
[REV] = concentration of intermediate receptor REV 
[.4i2£;.4] = concentration of intermediate receptor AREA 
Moreover, we have 
[C] = [C.] + [C,], [c.] = 
so that 
IC ] = 
Now we apply the law of mass action to (2.1) to obtain 
w 
dt 
« 
dt 
M 
dt 
d[U]  
-ki[RE][V] + k.,[REV] 
kolREV] 
A:6[Ai2£;^] 
d t  
^ = -k,[RE][V] + {k.,-\-ko)[REV] 
= -A:5[A][iE£:^] + (&-5 + ^ 6)[Ai2£r.4] 
dt 
Re 
It  
= k , [RE] [V] - {k . , -^k2) [REV]  
• — (^-5 -f- ^6)['A-^BA] 
d t  
Since protease decays naturally, the second equation of (2.4) must be modified to read 
^ = I^[RbV\-AC] 
12 
where /i is a decay constant. 
Initially, [i2£-K](0) = [A/2£r.4](0) = 0. From the fifth, sixth, seventh and eighth equations 
of (2.4) a simple calculation shows that 
[/?£](U) + [i?£l'1(«) = [/?£](0), 
[i2£A](«) + [AiiEA](t) = [REAm- (2.6) 
The Michaelis-Menten hypothesis asserts that dt[RE]/i[RE]f^i) = 5f[^£;A]/([^E.4]^'3) = 0. 
Therefore, combining (2.6) with the seventh and eighth equations of (2.4), we have 
_ W i O )  
[ ^]( ) ~ i  + u,[V]{t) 
-  i+.dvm 
ro 1/.^ [Rea]{0) 
- Twaiw 
f t p  i r n  ^ 3 [ f t £ : . - i ] ( 0 ) [ . - l ] ( 0  
where i/i = k i / { k ^ i  + ^2) a-nd 1 / 3  = A;3/(i'_5 + k e ) -  The first equation of (2.7) can not 
h o l d  a t  t  =  0  u n l e s s  t h e  i n i t i a l  c o n c e n t r a t i o n  o f  a n g i o g e n i c  f a c t o r  i s  z e r o .  . \ s  p o i n t e d  o u t  
in [25], this is because the assumptions that l/(/ti[/?£;](0)) = l/(/t5[i2£.4](0)) = 0 are not 
consistent with the number of initial conditions for the system (2.4). That is to say, we 
are dealing with a singular perturbation problem here. The equations (2.7) are only valid 
in deriving the "outer solution". We want the outer solution to be valid only for times 
t > € = maa:{l/(&i[i?B](0)), I/(A:g[i?B.4](0))}, and it must be matched with "inner solution." 
This argument is given in [25] in detail, [f e is very small we need only consider the outer 
solution. Combining (2.4) and (2.7), for t 2> e, we have 
m ^ k.uiivjiREUo) 
dt i-j-i/i[y] 
d[C]  _  WKKM2I  _  , . rn  
d t  ~  l  +  i^ i [V]  
dM _ fc6t^3[A][fig.4](Q) 
d t  1 +1/3 [A] 
d[h] _ A;6f/3[A][figM](Q) 
d t  ~  l  +  ^ '  
L3 
Our goal is to replace [i?£r](0) by [/?E](i) and [iZg^KO) by [i2£;^](t) and ultimately by [/V](t). 
From che first and third equations of (2.8), [V] and [.4] decay exponentially fast. (See [23] for 
a detailed analysis of this fact.). 
Therefore, [/2BV'](i) and [Ai?E.4](i) decay to zero exponentially. By the conservation laws 
(2.6), for large times, the positive quantities [/ifiKO) -[/?£](£) and [/2£:..i](0) -[i?f:.4](i) are very 
small. Thus, we can now replace [/Ee](0) by [RE]{t) a-nd [^b.^KO) by [fl£;.4](t). This results 
d [V]  ^  koux[V] [REm 
d t  i  +  v i \ y \  
m _ kou,[y][RE]{ t )  
d t  i  +  u i i v ]  
d [A]  ^  fc6 ( /3M[ /?S .4 l (0  
dt I +1'3['4] 
d[U]  ^ k6 l^3[A][REA]i t )  
d t  1 + f3[4] 
Next, since we have good estimates of the number of receptors per cell which can be observed 
under the microscope, we replace [/2£:](t) and [fl£^](0 by a multiple of[iV](i) in (2.9). It is 
reasonable to take [/?b](0 = ['i](0[-^](0i where [d"] is a function which is nearly constant. It 
is not unreasonable to take [d*] to be large since there are many receptors on the cell surface. 
Likewise, we take [REA]{t) = [<^a](i)[^^](0- Again, [d'a] is nearly constant and is very large. 
Therefore, we have 
m ^ 
d t  
_ At[K][iV] 
d t  ~  i  +  t / i [ y ]  
M = 
d t  1 + j/3[.4] 
m _ Hmi  
d t  ~  i  +  t /3 [4 ]  '  
where Ai = SkiUi, As = Sak^uz. 
Similarly, if we apply the standard Michealis - Menten kinetics to the third and fourth 
equations of (2.1), we obtain 
d{F\  . HCa][F]  
d t  1-1- i/of-f] 
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where Aj = ^4^2 and U2 = Also, since the endothelial cells produce fibronectin [42], the 
above equation must be modified to read 
where /o is maximum value of the concentration of fibronectin. 
On the other hand, It is known that TAF and angiostatin are produced by ECs [18]. 
Therefore, the first and fourth equations of (2.10) should also include the production terms 
^([iV'] and <T2[A'], respectively where <7i and (Tt are some positive constants. .A.Iso, it is known 
that inhibitor decays naturally. Therefore, the last equation of (2.10) should have a decay term 
M3[-^a] where is a positive constant. 
Therefore, we now have together with (2.11) 
where Ai = A3 = Safc^u^ and Co, is given by (2.3). 
In our model we will use literature values (see section 4.3) either m v ivo  or in  v i t ro ,  when 
no in vivo constants are available. Therefore, since the constants A^ and i/,- (t = 1,2,3) are 
identified in terms of kcat and Km in the literature, we need to redefine them. In the litera­
ture, 1/1 = l/K^, k2 = and uz = l/ZC^, Are = k^t- Here, 
we set C = = C = K^ = k^,, = 
A'4 = other hand, if we define S  =  — and Sa  = — where 
''0) '"ao > % are some reference numbers for density of angiogenic response receptors and for den­
sity of angiostatin receptors and for number of ECs per liter, respectively, then (2.12) now 
(2.11) 
1 + Vi[V] 
^{fo -  [F])[F][iV] 
A3[>1][^'] ,, 
(2.12) 
n o  
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reads 
I f  -
fEl _ iLrsIEM _ „rri 
fl = /5(/o-[F])(fi[<vi-^^[fl[a] 
5[A] ^cat''aoM[^^] , _ r.yi 
aw 
-W -  itiTMh; 
We assume a capillary wall is located on an interval [0, lo]  on the y  axis and a tumor is 
located at i = l[. We can imagine the tumor vascularization problem as shown in Figure 2.2. 
We are assuming that a T.AF source is located at a subinterval of the line x = li. In our 
model, this source will be represented mathematically as a flux of TAF by a function Vi[ij,t) 
(see eqn. (2.38)). .Alternatively, one can take Vi[y,t) = 0 but represent the tumor source of 
growth factor as a forcing term, Vr{x,y,t) in equation (2.15) below. 
Now we define the notation to distinguish values of the concentrations of the biological 
variables in the capillary from their values in the ECM (Table 2.1). 
Extra Cellular Matrix 
(ECM) 
h  
Figure 2.2 ECM 
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Table 2.1 Notation 
Chemical Capillary ECU 
[V](t) " ( y , i )  Vix ,y , t )  
[Cl(t) c ly . t )  C{x ,y , t )  
[ F m  f { y ,  t )  F{x ,y , t )  
a(y.O A(x,y,0 
[4](0 U{y , t )  U{x ,y , t )  
[Ca]{ t )  Ca{y , t )  Ca{x ,y , t )  
[C.](i) Ct(y, t )  Ci{x, y, t )  
Thus, we must write down versions of (2.13) twice, once for the capillary variables (u, c, /, a .  
and  once  fo r  the  ECM var iab les  (V,  C ,  F,  A ,  la ) .  
Remark 1: .A.s remarked in [50], the rate laws for the chemical mechanisms in the capillary 
must also include a term which takes into account tumor emitted angiogenic factor. That is. 
we  v iew th i s  fac to r  a s  be ing  suppl ied  f rom the  tumor  to  the  wal l  a t  a  ra te  Ur{y , t ) .  
On the other hand, any angiostatic factor must be supplied at a rate, ar{y,t), sufficient 
to inactivate the tumor. .A. reasonable choice for Ur might be a constant function since this 
function could be supplied intravenously at a constant rate [22]. 
Therefore, in terms of the new notation, the capillary equations should read 
dv ^^t''ovr] 
d t  + V)T]Q 
dc  
-1- Ur{y , t )  
-HC d t  +  
I = 
da  
§ = 7^^-"3'. (2-») 
d t  [K^  T  a) T] o  
where 
Uriy , t )  = AoH{V{0 ,  y ,  t )  -  Vo)Vt{0 ,  y ,  t ) ,  a^Cy ,  t )  =  AiH{t  -  to)  
for some positive numbers .4o, Vg, .4i, to .  Here, H{x)  is the Heavyside function which is 0 when 
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X <  0  and 1 when x  >  0 .  Notice that Vr  is coupled with the ECM variable, V. Here, 
c Ca = T— T-. 1 + 
In the ECM we have the same chemical kinetics. However we assume the diffusion of 
angiogenic factor, protease and angiostatin in this region. .A.lso, we introduce porous medium 
diffusion transport terms in Vj, C't and At equations. .A.lso, in the Ft equation we introduce 
motion by mean curvature. Therefore, in terms of new notation we have the following system 
of equations in two dimensions in the ECM. 
dV /  \  rnV' V 
= V.(^Dv(i.y)V(V-")j + + (m > 1) 
D. ,{x .y )V{Any  +ar{y , t )HiF  -  h)  
y-zU (2-15) 
£A \ k-Lr ,„AN 
d t  
d ig .  _  k-^^ t r^^AN 
d t  (A*^ l+.4)% 
C =  Ca +  Ci ,  Ci=- .u ,UCa (2.16) 
so that 
Ca = r-^. (2.17) 
1 + t/Ja 
Here Vr{x ,y ,  t )  is a source function which may be zero and is some positive constant. 
Remark 2: It is reasonable to have a source term ar{y , t )H{F — /:) in the .4£ equation 
as in the at equation, since angiostatic factor is supplied not only in the capillary but also 
throughout the circulatory system. Here /2 is a positive small constant. 
In this model, we allow the diffusivities Dv,  Dc ,  Dp and to depend on the material 
properties in the ECM. However, for simplicity we take them to be constant since we do not 
know the exact structure of these functions. In their model, Sheratt & Murray (1990) estimated 
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the diffusion constants for cells and various chemotactic chemicals. Yamada (1978) estinaated 
the diffusion constant for fibronectin. Since we know the molecular weights of protease, T.A.F 
and angiostatin, we can estimate the diffusion constants for protease and angiostatin. (See the 
numerical experiments section for details.) 
.N^ow we couple the variables in the ECM to those in the vessel wall with the following 
equations: 
V r{y , t )  =  AoHiV{0 ,y , t ) -Vo)V, i0 ,y , t )  (2.18) 
N{Q,y , t )  =  vr}{y^ t )HU\  -  /(tf-O) (2-19) 
SV" 
~DviO,y)-^[0,y,t) + aiV{0,y,t) = ti;iv{y,t) (2.20) 
dC^  
-Dci0,y)-^{0,y,t) + o'3C{0,y,t) = mciy,t) (2.21) 
jm 
-£).A(0, t/)-^(0,i/,0+ a2--l(0, i/,0 = ha(yit) (2.22) 
for some positive .4Q ,  Vq ,  ai, ao, as, 0, ip i ,  ip i ,  ^ 3. /i-
Here 0,'s are constants needed to correct any losses in passing from the outside to the inside 
of the vessel wall or vice-versa. Here Vq is a threshold constant. Equation (2.18) tells us that 
when K(0, y, t) < Vo, the capillary equations are passive, that is, the concentrations on the 
boundary do not change in time. The meaning of (2.19) is that endothelial cells will not enter 
the vessel wall in time, unless the basal lamina is sufficiently thin, i.e., fi > f[y,t). However, 
as soon as ^(0, y,t) > Vq and /i — f{y, t) > 0, the source term for T.\F induces new dynamics 
on the inner vessel wall itself, and the ECs begin to change in time and penetrate the ECM 
from the interior wall of the vessel to reach the tumor wall. Finally, equations (2.20), (2.21) 
and (2.22) couple (via the Robin conditions) the fluxes of K, C and .4 just outside the capillary 
wall to their values (u, c, a) in the capillary itself. 
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2.2 The role of reinforced random walks 
We consider the capillary wall to be a one-dimensional lattice with endothelial cells (as­
sumed to be a mono-layer of equal size and shape) equally spaced and in non-overlapping 
contact located at reference points nh along the y axis. Here, we will use the idea explained 
in [31] in detail. 
Let f^(.) be the transition probability rate per unit time for the one-step jump of an 
endothelial cell at site n to site ra-1-1 or n — 1 respectively. Let 7n(0 be the probability density 
distribution of the endothelial cells at position ri G Z at time i, conditioned on the fact that it 
begins at n = 0 at t = 0 and evolves according to the master equation: 
That is. will be augmented by cells moving from the position n^F l to n and diminished 
by cells moving from n to either n-l- 1 or ra — 1. The quantity "'s the mean 
waiting time at site n. The transition probability rates f^(.) depend on control substances 
which we denote by W are defined on the lattice at ^-step size. The control substances W are 
very general and in this thesis we will take it as a function of fibronectin, / and proteolytic 
enzyme, c. The vector W is given by 
where W n  =  W n( / , c ) .  
Suppose, as suggested in [31] that the decision of "when to jump" is independent of the 
decision of "where to jump." Then the mean waiting time of the process is constant across the 
lattice. Hence, the the transitions may be suitably scaled and normalized. Let the scaled 
and normalized transition rates be and depend on W only at the nearest neighbors 
W = , tu-n, _„+i. ifo. 1/2. •••) 
Thus, 
(2.24) 
and 
(2.25) 
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where A is a scaling constant. 
This renormalization introduces longer-range dependence of the transition rates on the 
control species, because 
, . 
and the master equation now has the form 
<^n-Onn- l  + "'n+flWl 
u;^^p]r/„. (2.27) 
[f we use the fact that iV"*"(«, u) = l - N~{v .  u), we obtain the continuous limit of the master 
equation: 
^ - n 
d t  ' '  c? i /  V  dy  
= 'D,3j:-(77^(lni) ) (2.28) 
where T){y ,  t) now denotes the endothelial cell density and where f is the so called transition 
probability function. Here, 
Dr, = lim Xh^ 
•0,A—f+oo 
and y  =  nh  where h  is mesh size. (See [31] for details of the derivation of (2.28) from (2.27).). 
This function has the effect of biasing the random walk of endothelial cells, [n this case, we 
know that the walk is influenced by the active proteolytic enzyme it produces in response to 
the angiogenic factor that has made its way to the ceil receptors and by the fibronectin in the 
BL, i.e., we write 
f = f(c„,/). (2.29) 
A simple transition probability which reflects the influence of enzyme and fibronectin on the 
motion of endothelial cells is f(ca, f) = for positive constants 7,-. [23]. 
The biological interpretation of this choice is that endothelial cells prefer to move into the 
regions where is large or where / is small. 
In order to avoid singularities in In f and its derivatives in this equation, it is useful to take: 
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where the a,-, 6,- are constants such that 0 < oi << 1 < aa and 6i > 1 >> 60 > 0. Clearly, f is 
not singular for small or large values of c^, f and will approximate over a considerable 
range of these variables. (See [23] for detail). 
In two space dimensions, we use a square grid, and analogous to (2.25), we define the 
renormalized transition probabilities as 
f(u,y .  z)  = 4AiV(«, J,, z) = (2.31) 
The resulting master equation is the two-dimensional analog of (2.27). Therefore, we have the 
following equation as the continuous limit of the master equation in two dimensions: 
where 
Div = lim A/i". 
Furthermore, we have proliferation of EC's in the ECM. We view the proliferation rate 
as a sum of the proliferation response to T.A.F. protease and ordinary proliferation. In this 
model, we will use the proliferation rate as a sum of the proliferation response to TAF and 
ordinary proliferation. In the literature [14], the proliferation response of EC's to T.\F has 
been reported. However, it is known that the turnover rate of TAF to protease via ECs is 
far more rapid than the mitosis response rate of EC's to protease. Therefore, we regard the 
proliferation of EC's as responding to protease in the same way as it does to TAF. That is, we 
write N = N{Ca, t) so that 
dt  dCa d t  d t  
= proliferation due to protease + proliferation due to natural cell mitosis and death 
where 
ON N 
a t  7o  
is the ordinary proliferation term. Here 70 can be taken to be Mmax-  If we fix t ,  N  =  
(G(Ca) -I- 1)NQ. Here, NQ is the initial number of cells at a fixed time t and G{CA) is the 
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biphasic response function of cells to protease. Therefore, we have 
dN _ iVG'(Ca) 
dCa ~  l+G(Ca) 
so that the total proliferation of cells is 
It is known that EC's do not proliferate until Ca, the active enzyme is above a threshold value 
Ca- This is accounted for by writing the proliferation term (2.33) as 
+ TTW) 
Curvature is a measure of the surface area to volume ratio. The larger this number, the 
more efficiently nutrients might enter the cells and stimulate proliferation. Therefore, It is 
reasonable to multiply the proliferation term by a function of curvature so that (2.32) now has 
the form 
a'V f  f  N  
=  V-  Dy(x . t / ) :VV la  
d t  y  •  ^  ^  \T (Ca,F)  
where Q is a function of the curvature, K such that Q(0) = 0, Q' ix )  >  0. In the numerical 
e.Kperiments section, the structure of the functions G and Q will be discussed in detail. From 
now on, we will set 
W{N,Ca)= 
H-C?(Ca) 
for notational convenience. 
We take the probability transition rate function, f  to be of the same form (Al-tough not 
necessarily with the same values of the constants) as the f. 
2.3 Boundary and initial conditions 
The system is closed by imposing the following boundary and initial conditions. At the 
capillary (x = 0), we have zero flux boundary condition for fibronectin in the ECM, that is 
F^(0,j/,0 = 0. (2.36) 
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At tumor side (x = /i), the flux of EC's is carried out the region by ECs. That is, for some 
nonnegative number we have 
At this side, the fluxofTAF into the ECMis driven by the source function V[^{y , t ) .  Therefore, 
Dv{luy)^{h ,y , t )  =  Vl iy , t ) .  (2.38) 
Also, at (i = li), we have zero flux boundary conditions for angiostatin. enzyme and fibronectin 
in the ECM, that is 
QArn  
= 0 (2.39) 
Dc{iuy)^{ii,y,t) = 0 (2.40) 
DF^{li,y,t) = 0. (2.41) 
.At y  = 0,/2, we impose zero flux boundary conditions for both capillary and ECM variables. 
Therefore, we have 
D!^{x,y)N4-lti(^^ ^ = 0 (2.42) 
^  dy \T{C^ ,F ) J  
gym Qym 
Dvix ,0 )^{x ,0 , t )  =  Dv{x , l2 ) -^{x , l2 , t )  = 0 (2.43) 
Dc{x,0)^{x,0,t) = Dc{x,l2)^{x,l2,t) = 0 (2.44) 
dF d f  
DF^{x,0,t) = DF-^{x,[2,t) = 0 (2.45) 
DA{x,0)^{x,0,t) = DAxJ2)~{x,l2,t) = 0 (2.46) 
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Initial conditions: 
in the ECM, 
iV(x, t/,0) = V'(i, (/,0) = Cfi, (/,0) = .4(i,i/,0) = /a(a:, (/,0) = 0, F(x,y, 0) = 1 (2.48) 
while in the capillary, 
c(y, 0) = v{y ,  0) = a{y ,  0) = ia{y ,  0) = 0, r?(y, 0) = f {y ,  0) = 1. (2.49) 
We take the function Vi iy . t ]  is of the form: 
^L{y-t) = i''oKp[l - cos(27rj/)]''e,xp(-0iO- (2.50) 
Here yo, is the so-called dosage. Kp is a normalizing constant and p > 0. (See section (4.3) 
for details about this function.) VVe are assuming that in the avascular state, the tumor 
emits chemotactic agents which, if the tumor Is not supplied with sufficient oxygen, will decay 
with time as the tumor dies. The decay rate, 0i, can be thought of as a measure of the 
survivability of the tumor in the avascular state. (The half-life is ln2/0i). In a real system, 
01 > 0. However, to test the model in the worst case, we take 0^ = 0. 
We consider two cases for the angiostatin, which must be introduced into the blood stream as 
a therapeutic agent: 
o - r{y , t )  = 0, 
as it would be in a case in which no therapeutic agent is present, and 
ar[y,t) = .4.1 > 0 
which would be the case if the agent is uniformly distributed throughout the circulatory system. 
n ^ I 
r(Ca, /) 
= 0 (2.47) 
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3 
A MATHEMATICAL ANALYSIS OF THE MODEL 
3.1 A mathematical analysis for the capillary equations 
In this section, we study a mathematical analysis of the endothelial cell density equation 
(2.28) with the boundary condition (2.47) and with the assumption that c{y,t)a.nd are 
in quasi-steady state. Here, by quasi-steady state, we mean that we will look at the behavior 
of r]{y,t) as i 00 in the case that c{y,t) and f{y,t) are time-independent. We also assume 
that ar(i/, t) =0 so that Ca = c. Since r(c, /) = ri(c)ro(/) where 
we have 
(3.1) 
Here c  and / depend on y  only. Let 
(.3.2) 
Therefore, (2.28) now reads 
(3.3) 
with the boundary condition 
r/j, - 7/S(i/) = 0, at y = 0,1 (3.4) 
and initial condition 
l{y,0) = 1 (3.5) 
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where 
S(i/) = Q(c)c, 4-«?(/)/„. (3.6) 
Since r]{y ,0 )  is nonnegative, it follows from the strong meiximum principle, that r][y , t )  is 
nonnega t ive  fo r  a l l  t  >  0 .  We so lve  (3 .3 )  us ing  separa t ion  of  var iab les  by  se t t ing  r]{y , t )  =  
T{t)N{y) to obtain 
^T^XT = 0,  D , - ;V - NSly)  dy  -h XN = 0. (3.7) 
From (3.7), it is clear that T{ t )  is of the form exp(-/\i). We make the substitution iV = aZ,  
where a = explf^ S(C)<^C) [-^9] to obtain the classical Sturm-Liouville problem for Z, namely 
c'y. 
= AaZ, Z'  =  0  at t/ = 0,1. (3.S) 
It is known that this problem has a complete orthonormal set of eigenfunctions Z,(f/) in 
the weighted Hilbert space Lj(0,1) with eigenvalues A,- ordered as 0 = Aq < Ai < Ao < • • •. 
The eigenfunctions of (3.7) with boundary condition (3.4) are then given by iV,(i/) = 
(T(y)Zi(y). The eigenfunction corresponding to A = 0 is given by 
iVo()/) =exp^^ 5(C)< 
Notice that 
(Z ,  Uz)  =  -Dr,  r ZicrZydy  = D, T (r(Z')-dy > 0, 
Jo  Jo  
since Z' = 0 at i/ = 0,1 and (T{y)  is positive. On the other hand, we have 
(3.9) 
(3.10) 
which implies that 
(Z,-£Z) = (Z,AZ) = A1|Z||2 (3.11) 
<7 
. = ^ ^>.0 (3.., 
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for i = 1,2, • • •• 
It is also clear from (3.7) that 
Ax- r >fi{y)dy = 0, (3.13) 
Jo  
showing that the eigenfunctions /V,(t/) { i  =  1,2,...) have zero mean value. (See [49]). 
By standard expansion theory, we have 
CO 
r i {y ,  t )  =  BQNo{y)  -f- ^ B,iV,(y)e"'^*', (3.14) 
i=l 
where the coefficients are determined by setting t = 0 and using the orthogonality properties 
of the eigenfunctions. From (3.14), we have r]{y,t) BoNQ{y) as t co. 
Notice that 
= In 
which implies that 
.^r/.A _ n(c(i/))r2(/(y)) 
It is easy to see from (3.14) that by setting t = 0 and integrating both sides over [0,1] and 
using (3.13) we get 
Bo = 77 . (3.17) 
fo 
Example 1. Let c(y )  = ^ y"(l - y)" and /(y) = 1 - Sy"*(l - y)*" for 0 < y < 1 where 
A = 28x10", n = m = Wand B = 0.22x10®. Notice that c(0) = c(l) = Oand /(O) = /(I) = 1. 
In this case, we have 
02 6; -hi ai + .4y"(l - y)'^ 61 + 1 - By^'jl - y)^ 
' ai 61 + 1 aa + Ay"(l - y)*^ 62 + 1 - 5y'"(l - y)'"' 
Therefore, in this case the steady-state solutions can be represented as in Figure 3.1. 
28 
3.5 
< c(y) 
n(y) 
2.5 
0.5 
0.2 0.1 0.3 0.4 0.5 
y 
0.6 0.7 0.8 0.9 
Figure .3.1 Steady state solutions for EC concentration, Enzyme Concentra­
tion and Fibronectin Concentration. 
3.2 A mathematical analysis for the ECM equations in the absence of EC 
proliferation 
In this section we present a mathematical analysis for the ECM equations in the absence 
of EC proliferation. As in the section (3.1), (2.32) can be rewritten in the following form 
- n  
SR-"" (3.19) 
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where 
P = n{C)C,+ i ( ; {F)Fr ,  Q  = fi(C)C, 0(F)F,. 
Also, (2.19), (2.37) with = 0 and (2.42) now read 
N =  i)T]{y ,  t )  at z = 0, 
iVj. — iVP = 0 at I = 1, 
Ny -  NQ = 0 at y = 0,1 
(3.20) 
(3.21) 
(3.22) 
in the case f i  >  f {y ,  t ) .  
.\gain, as in section (3.1). we are interested in the behavior of iV(i, t / ,  t) as i -> oo in the 
case  C( i ,  t / ,£ )  and  F{x ,y , t )  are  on ly  func t ions  o f  y .  Let  us  cons ider  C  =  c{y)  and  F =  f{y)  
for simplicity. Therefore, for this particular choice we have P = 0 and Q = S{y) where S{y) is 
given by (3.6). 
Recall we have as  t  oa ,  T]{y ,  t )  -> BoNoiy) .  The equations (3.19)-(3.22) now read 
•.V„+|(=V,-.V5) 
iV = i/jBoNoiy) at X = 0, 
Nx = 0 at I = I, 
iWy  — NS  =  0  at(/ = 0,1. 
Now let 
R' (x ,y , t )  =  iy (x ,y , t )  -  (1 -  x f^BQiYo{y) .  
Therefore, with this new notation, (3.23)-(3.26) have the following form 
(3.23) 
(3.24) 
(3.25) 
(3.26) 
= -Div Kxx  d t  
K  = 0 at X = 0, 
+  9 i y ) ,  
Kx = 0 at I = 1, 
Ky — SK =0 at y = 0,1 
(3.27) 
(3.28) 
(3.29) 
(3.30) 
where g{y)  =  2i l }BoNQ{y) .  
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First, let's solve the homogeneous part of this equation by separation of variables. Let 
K = U{x,y)T{t). Then, 
d  
T '  +  XT = 0, D,v 
together with the boundary conditions 
f/x - su ^  + XU =  Q 
U = 0 at X = 0, 
Ux = 0 at I = 1, 
Uy -  SU = 0 at y = 0,1. 
Clearly T has the form exp(-Af). Now let U{x ,y )  =  X{x)Y{y) .  Then we have 
(3.31) 
(3.32) 
(3.33) 
A'" + 
;V 
0, .Y(0) = A"(l) =0, 
4-{Y ' -  SY)  +-^Y  = 0 .  r ' - s r  =  0. at y = 0,1 
ay Um 
(3.34) 
(3.35) 
so that X =  i / - \ -  n .  Then, it is easy to see that the eigenvalues for the boundary value problem 
(3.34) are Un = D,\f{n + :t)^~' (" = 0) Ir"- • ••)• -"^Iso, the corresponding eigenfunctions are 
.\rn(x) =sin On the other hand, as was proved in section (3.1). the eigenfunction 
corresponding to /z = 0 is Yo{y) = i^oiv) and m > 0 (i = 1,2 • • • )• 
Now, let us define the following operator: 
K„ +  ^ (K , -Ks ' j  = D.v 
We have the eigenfunction expansion as follows: 
K = ^  Ck{t)(pkix) so that Kt  =  CK +  g{y ) .  
k  
Then, we have 
4(0 =  -Ck{ t )h  +  9 k ,  where gk  =< g ,^k>  • 
Therefore, Cfc(t) = 4- where 
ak  =  - i ^Bo  [  [  { I -  i)^iVo(y)9jfc(x)(fxtij/. 
Xk Jo  Jo  
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Example 2. Let 
l-cie-^" l-cae'^s' 
where ai = 1.7, Oo = 2.5, bi = 2, bi = 0.004, ci = 1.2, co = 2.015, C3 = 0.7, C4 = 0.28. Then, 
it is easy to see that 
f y  ^  1 1  
and-(61 4-/) (62 +/) 6o — 61 (oi + c) (a2-f-c) ai — o>i 
Therefore, we have 
5(,,, - lIMc + ^ / 
yi(a2-ai) 72(^2-^1) , 
, n/v (ai 4-c)(a2-f c) (61 + /) (62 + /) 
= 7i + 72 = 2, 
^ p2y 
.Vo(i/) = expy j^  S{Qd(^ j  =  e  
and 5o = -71— = • 
fo  yo(y )dy  ~  ^ 
In this case, (3.35) has the following form. 
Y"-2Y '  +  ^ Y  = Q.  Y ' -2Y  = Q at y = 0,1. 
Dy 
The eigenfunction corresponding to /x = 0 is Vo(l/) = e*''. Also, the nonzero eigenvalues are 
= Djv(l + (m = 0,1 • • •) and the eigenfunctions corresponding to Hm are 
Ymiy)  = e" ^  mx cos miry  + sin mi:y^ . 
Recall that the eigenvalues for (3.34) are i/„ = D,v(ti + 1/2)"t^, (ra = 0,1 •••) and the 
corresponding eigenfunctions are 
Xn{x) = sin (n -f- l/2)?ri 
Let the e igenfunction expansion of K be 
00 00 
n=0 771=0 
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where 
Here, 
'^m.n 
9m,n  —^  ^~  f  f  9 iy )^m. ,n^^^y-
Jo  Jo  
Recall, g{y)  = 2i l )Boe '^  and A^.n = + fn for n, m = 0,1 • • • where </' is as given in Table 
4.1. It is easy to see that 
AQ.O = 0,vx> -^o.n = Av(n + 1/2)-T-, Am,o = ^iV 1 4- (m- + 1/4) 7r* 
Arn.n — ^iV 1 4- + (re + 1/2)2^ , jq.o = >PBo^, go,n = ^Bo^on+iW 
jn..Q = 8m0go''J;Xr\ = C/o,o = e-''sin(7rx/2), 
Uo,TI = e'^sin (n4-l/2)7rr , f/^.o = sin(ffi/2)e^^m7rcos(mffi/)+sin(m7ri/)^ , and 
f/m,n = sin (n 4- l/2)7ri e^l mffcos(m7ri/) +sin(mn-i/) ). 
Therefore, Cm n(0 as f -f oo since n > 0 for n, m = 0,1 • • •. As a result, as  t  oo  
' «' TTl, rt * 
we have 
K +f +f;  +f;  f ;  
'^O.O ^ ^0 ,n  Am.O ^ ^m,n  71=1 m=l a=l ms:! 
and therefore 
N i jBoi l  - x fe - ' '  -(- f^C/o.o + S . wu,u • / ^ \ -'U,/* • / ^ \ ' / , / ^ \ 
n=l m=l n=l m=l 
Since these series converge rapidly, it is not unreasonable to take the first ten terms of these 
sums for the numerical simulation of this example. The following figure shows the behavior of 
the endothelial cell density in the ECM as 4 ->• oo in the case that C{x,y,t) and F(x,i/, t) 
a re  on ly  func t ions  o f  y .  
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Figure 3.2 a. Enzyme concentration and Fibronectin concentration, 
b. Endothelial ceil concentration as t -y oo when 
C(x, y, t) and F(x, y, t) are functions of y only. 
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4 
CONSTANT SOLUTIONS AND NUMERICAL EXPERIMENTS 
In this chapter, we first examine the constant solutions of the capillary and ECM equa­
tions described in the previous chapter to nondimensionalize the model for future use. (See 
Appendix II). Then we will determine the parameter values used in the model. As much as 
possible, the parameter values are taken from real experiments either in uivo or in uitro, when 
no in vivo constants are available. 
Remark 1: Suppose r j ^ ,  v^ ,  Cj, /«, i a , e ,  cte are the constant solutions for (2.14) while Ng,  V'e, Cg, Fj, 
/a.e, Ae are the constant solutions for (2.15). If we nondimensionalize the system of equations 
(2.14) and (2.15) by constant solutions (see .Appendix II), we see that the following relation­
ships must hold: 
,, W — n A — T rt — ^cat''0^e _ 
* ~ — 'd.ei ' e  — ^ei — 'a,ei ,  r -y  , „ ' 2 — / r-4 , x 
because we have the same biological constants for the equations Vt and Ct and for the 
equations at and i^, in (2.14). Likewise, we have the same biological constants for the 
equations Vt and Ct and for the equations At and la, in (2.15). 
Remark 2; Since Vg = Cg and Og = I'a.ei from (4-1). (4.2), (4.3) and (4.4) we have 
W3^'m TJg — " TTy  S-Hd TJg  — 
- r}o<Ti ' 
•Also, since Vg = Cg and Ag =  Ia ,g ,  from (4.6) - (4.11) we have 
iVg = Vg — Cg and Ng = Cg. (J l  Qfx (T i  a3 0*2 Oil 
Furthermore, since Vg = Cg, from (2.20) and (2.21) we have 
ai  03" 
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4.1 Constant solutions for capillary equations 
VVe say that the capillary is at rest if r] ,  v ,  c ,  / ,  a ,  ia  are all constants. Consider the case 
Vr = dr = 0. We have used the approximation 1 +- fol« 1 since /o « IQ~'^fj.M and 
= 0.83/xA/. Therefore, if 7e 7^ 0, from (2.14) the constant solutions are 
(4.1) 
«cat''0 - r]o(Ti 
c, = ^ (4.2) 
«..= = — (4.3) 
/^3 
a. = (4.4) 
«caf'*ao -
f e  = /o -  -Tiife—Ca,, Or /^ = 0 (4.5) 
Q 
where Ca.. = — and /o is the maximum value of concentration of fibronectin. .\lso, note 
1 "I" 
that in order to have a biological meaning, one must have k^at'^o > > '70^2. and 
A  > 0 .  
If T/e = 0. then it is easy to see that the constant solutions for (2.14) are [rjg, Vg, Ce, fe,ae, ia.e) = 
(0,0,0,/e, 0,0), where /« is arbitrary nonnegative constant. 
4.2 Constant solutions for the ECM equations 
Now suppose that N,  C ,  V ,  F ,  .4, U are constant and Vr{x ,  y ,  t )  =  0. Suppose that V[ ,{y ,  t )  =  
Pq for some constant Pq. Then, from equation (2.37), V[,{y, t) = Pq= 0. Therefore, if /Vj ^ 0, 
from the first equation of (2.15) we have 
V, = = V,. (4.6) 
«cot''0 - V0<^1 
Similarly, from (2.22), we have 
4. = ^ a,. (4.7) 
07  
From the first and the second equations of (2.15) we have 
C, = (4.8) 
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From (2.21) we have 
(4.9) 
Therefore, 
(4.10) 
Also from the fourth and fifth equations of (2.15) we have 
la,. = -iVe- (4.11) 
From the third equation of (2.15), we have 
Fe = /o - or Fj = 0 (4.12) 
where In order to have a biological meaning, one must have k^at''o > lo'^i 
and Fe > 0. 
If iVj = 0, then it is easy to see that the only constant solutions are {Ng, Vg, Ce, F^, .4e, /a,) = 
(0,0,0,0,0.0,0) and (iV„ V;,Ce,F„/ie,/aJ = (0,0,0,/o,0,0,0). 
We now have a complete set of constant solutions for both capillary and ECM equations. 
4.3 Numerical experiments 
Whenever possible, in  v ivo  experimental data was used to estimate the parameter values. 
If this was not possible, then we either used in vitro experimental data or chose values for 
illustrative purposes. Although we nondimensionalized the time in Appendix I and Appendix 
II, from now on we will use the time scale in hours [23] as was used in most of the literature 
values. 
The length scale. We take capillary-tumor distance, li = IT/xm = 0.0017cm and the length 
of the capillary, = lOO^m = 0.01cm. 
Estimation of the diffusion coefficients. In their model, Sheratt & Murray (1990) used 
values of D/v to be in the range 6.9 x lO'^^^cm-s"*^ — 3.5 x 10~'^''an^5~'^ for the diffusion of 
cells. They also used values of Dv to be in the range 3.1 x 10~'cm^s~' —5.9 x 10~®cm's"^ for 
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the diffusion of chemotactic chemical. Yamada (1978) estimated the diffusion of fibronectin to 
be < 5 X Accordingly, we take and Dp =  lQ~^^cTnrs~^ .  It is 
well known that the molecular weights of protease, TAF and angiostatin are Mc « 10® daltons, 
Mv ~ 1.65 X 10® daltons, and Ma  « 3.8 x 10"* daltons, respectively. ( 1 dalton = 1.66 x 10"-'' 
gram.) It is reasonable to assume, for large molecules such as proteins that the molecular 
weight is proportional to its volume. In other words, if we have two proteins that have molec-
/ 2 
ular weights :Vr and A'P, respectively, then ;V/' « C(47r/3)r? and f iV/'/iVPj = ^ = 
Here C is some positive constant, r,-, rj are the radii, and D', are the diffusion constants of 
the substances . Therefore, we use the following approximations: 
D v  «  1 0 ~ ® D c  ~  1 0 " ® c m - s ~ S  s ;  1 . 8  x  1 0 ~ ® c m - s " ' .  W e  t a k e  £ ) , V i  =  ^  ~
0.0125/1-', Avj = ^ a 3.6 X iQ~^h-\Dc, = ^ « 12.45/i-', Dc, = ^ ~ QMh-\Dv, = 
» 1.2h-\Dv, = ^ s; Omh-KD^, = ^ ss 22A2h-KD^, = ^ s; 0.648/l-^ and 
D„ w3.6x lO-^/i-^ 
The proliferation rate 9  and the death rate yuo. Some proliferation rates for ECs have 
been found in the literature. For example, in [36], the authors give 0.04/1"while in [37], the 
authors give 0.056A~'. We took 9 = 0.056/i-^ Some death rates for ECs have been found in 
the literature. For e.xample, in [10], the authors give 0.005/day while in [3], the authors give 
0.12/day. We took H2 = O.OOS/i"'. 
Enzyme decay rate n and inhibitor decay rate ^13. Since these decay rates are very 
difficult to measure m vivo, we take them to be /x = /i3 = 0 for illustrative purposes. In the 
m = 1 and Dp  ^  0 case we took /i = 4.56/1"^ [51] for illustrative purposes. 
Estimation of initial density of ECs rjp and initial density of fibronectin /p. Haas 
& Duling (1997) estimated the length of a cell in the range 94/xm to 141^m. Nerem k  Levesque 
k  Cornhill (1981) estimated the width of a cell in the range lOf im to 18^m. It is also known 
that the thickness of a cell is about l^m. Therefore, a simple calculation shows that there are 
about 10^2 ceils per liter. Hence, we took t jq  = IQ^^ce l l s f  l i t e r .  (See [23]). Also, the density of 
fibronectin has been estimated by Terranova (1985) [40] to be /o = IQ-^/xM. 
Estimation of density of angiogenic response receptors rp and angiostatin receptors r^ .  
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The number of receptors per ceil, 5  is estimated to be in the range 150000 [46] to 175000 [39]. 
Thus, we estimate tq = STJQ = 1.5^M and = L.TSFIM. However, we take tq = L^IM for 
simplicity. 
The fibronectin productioa rate p and death rate Yamada & Olden (1978) es­
timated the generation time of fibronectin to be 18/i. .Assuming that /o units of fibronectin is 
produced by TJQ cells in 18h ,  we estimated the fibronectin production rate as 
I8/70/0 
, 3  =  0 .22h~^  (See [23]). Fields (1990) estimated to be 16/i~^ for the hydrolysis of type I 
collagen (rat tendon) human fibroblast collagenase. 
Estimation of kinetic parameter K^.  Fields (1990) estimated to be 0.83/tiV/. 
Estimation of kinetic parameters and K^. The kinetic parameter esti­
mated to be 162Tnin"^ ([20]). was also estimated to be ([20]). 
Estimation of kinetic parameters Since we do not have a good estimate 
for and it is not unreasonable to take kf^^ = '2x k^g^^ and K-^ = 2 x as they have 
similar molecular structure. 
Protease inhibitor equilibrium constant t/g. Takahashi (1992) estimated Ifue in the range 
0.59 nmol/L to 2.4 nmol/L. Taking l/v^ = 1.0 nmol/L = nondimensionaliaation 
gives t/g = 1700. Recall that = L7/iM. 
Since To = St ]o  « 1/iM, we can take the constants Ai = u\  — Ao = 
we are now in a position to present some numerical computations for the following system 
of equations, together with the initial conditions 
c(j/,0) = i;(y,0) = a(y,0) = ia(i/,0) = 0, 7/(y, 0) =/(y, 0) = 1 (4.13) 
and 
iV(i,y,0) = K(x,y,0) = C(x,y,0) = A(x,y,0) = /a(x,y,0) = 0, F(x,y,0) = 1. (4.14) 
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First, at the capillary we have (0 < y < 1, i > 0) 
i • 
dv  XiVT]  
d t  1  +  f i v  
dc  _  Xivr j  
d t  L  +  f i  u  
U = m - n u -
- M C  
d t  1 -H U2f  
da  Xzar j  
d t  1 + u^a  
dia 'hav 
-'r(T2ri + ar{y,t) 
d t  1 + uza  - f iz ia  (4 .L5)  
where 
and 
so that 
ar{ya)  =  AiH{t- to)  (4 .16)  
C = Ca + Ci, Ci = UeiaCa (4.17) 
C a  =  — ( 4 . L 8 )  
1 +i/eJa 
Second, in the ECM we have the following equations: (0 < x,y < l,i > 0) 
dN-  _  d  
d t  dx  
+ + TT^) 
i - (T iN+Vr{x ,y , t )  ( m > l )  
Q { K )  
d t  
X iNV 
1 + t/iK 
££ = A 
d t  dx  (Dc.(x,,)|(C"))+|;(Dc,(..ri|;(0) 
n  fj :  ~2^rFyFs j , -h f ^Fyy  AaFCa 
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along with 
so that 
- + ar(!/, t)E(F - h) 
i i- 1^3'^ 
IT = 
C = C'a + C,-, Ci = UelaCa (4.20) 
l + uJ^Ca' 
where p  and q  are as in Appendix I. Also, the coupling equations between the capillary and 
the ECM are as follows. 
<PMy,  t ]  =  -hr^- 'Dv,  (0, y)  ^ (0, y ,  t )  +  ViO,  y ,  t )  (4.22) 
I 4}ia{y,t) = ZJ.Aj (0, y)-^(0, i/, t) + a2.4(0,y, i) (4.23) 
dC^ 
tiJ3c{y,t) = -/ir^~^Dc,(0,y)-^(0,y,0+Q!3C(0,I/,0 (4.24) 
iV(0,y,«) = i bT \ {y , t )H[ f i  -  f{y , t ) )  (4.25) 
for some positive constants ai, ai, Q3, tb, ihu 1^2. ^^3. A-
Moreover, the boundary conditions are as follows. 
At I = 0 : 
Fr(0,y,t) = 0. (4.26) 
At 2 = 1 : 
d V ,  
ro/iZ?vi(l,i/)-^(l,y,0 = VL[y,t) (4.28) 
dA^  
DA,{l,y)-^{l,y,t) = Q (4.29) 
(4.30) 
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dC^ 
Dci{hy)-^{i,y,t) = 0 (4.31) 
DF^il,y,t) = 0. (4.32) 
for some positive constant ^i. 
At y = 0,1: 
A v , ( i , ! / ) i ' V - ^ l n f  ^ ^  =  0  ( 4 . 3 3 )  dy  \T{Ca ,F )J  ^  
dV^ dV^ 
Dv , { i ,0 ) - ^ {x ,0 , t )  =  Dv2 ix , i ) - ^ {x , l , t )  = 0 (4.34) 
dC^ dmC^ 
Dcj(i,0)-^(i,0,i) = Dcji, 1)—^^(x, 1,0 = 0 (4.35) 
QP Qp  
DF-^{x,0,t) = DF—{x,l,t) = 0 (4.36) 
dA"^ 
DAj (x ,0 ) - j ^ (x ,0 , i )  =  D a 2( x , 1 ) -~ ( x ,  l , t )  =  0 (4.37) 
= 0 (^^-38) 
dy  \ r ( ca , / )  
where 
In our numerical computations, from now on we will take V£,(y, f) = V[ , (y ) .  This function 
has the following form 
VHW = 
vi,Kp(l - cos(^(!i - a)))' if J( e [o, 6] C [0,1], 
0 otherwise. 
(4.41) 
where VQ,  «p,p, a, b  are positive constants. The constant KP is chosen so that 
(1-cos(^^(y-o)))P<iy= L (4.42) 
Notice that the sequence {V£,(i/)} = {V£(y,p)}^i, forms a S  function as p ^ oo in the sense 
of distributions. The constant vq can be thought of as a measure of average rate of supply of 
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growth factor. In vivo constants are difficult to find in the literature, especially K^,  the 
decay constants /i, /ia and cr'-s. For this reason, we took fi = = ai = cr^ = 0. In fact, most 
of these constants can be calculated by the idea given in Chapter 4 (Remark 1 & Remark 2) if 
one can obtain all of the constant solutions ( see section 4.1 k section 4.2 ) from the literature. 
The sensitivity constants a,-, 6;, 7,(1 = 1,2) and the constants ib,>Oi,oei (' = 1,2,3) that are 
needed to correct any losses in passing from the outside to the inside of the vessel were chosen 
for illustrative purposes only. 
The biphasic response function G{Ca) in the proliferation term is of the form 
G{C,) = .42Cae.xp(-AC,-). (4.43) 
Here, the constants .Ao.A and the constant C° in the proliferation term have been estimated 
from a curve fitting to the data in [14] by the least square method. The graph of G(Ca) will 
be given in chapter 6. 
In the proliferation term, we have a factor Q{K)  where K is the mean curvature of the 
surface s = F{x,y,tQ) =constant. which is increasing in K and is nonnegative. The precise 
form for Q is not known, although it has been observed that the EC proliferation is greatest 
at the tip and almost nonexistent behind it. For want of a better choice of Q, we take 
(4.44) 
V l  +  
so that the maximum sensitivity is 1/e. We leave e as an adjustable parameter. 
4.4 Note on numerics 
The system of equations (4.17)-(4.38) were discretized in space dimensions using finite dif­
ferences and solved using the ode solver ode23 available in Matlab, which performs integration 
of ode's. The unit square domain was partitioned into a grid of 51 x 81. The solver automat­
ically adjusts the error tolerance depending on the smoothness of the solution in the desired 
integration interval. Since we have taken the length scales Ix and li to be very small numbers, 
the corresponding difTusion constants become large. Therefore, the computation time consid­
erably increased, especially in the porous medium case (m > 1). In the porous medium case 
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the equations are extremely stiff, so the alternative ode solver odel5s was used. We have not 
done a numerical stability analysis for our problem. Therefore, it is difficult to tell which ode 
solver is better for all cases. 
Furthermore, we also observed that almost half of the computation time is spent for f i y , t )  
to drop below the threshold constant /i when /i = 
W e  were amazed when we first discovered that a Matlab ode solver can solve as many as 
(6iV + 12) X {M +1) ~ 24000 odes where N = 50 is the number of grid points in the x direction 
and M = 80 is the number of grid points in the i/ direction. 
In Table 4.1, all volumetric units are in micro molarity the time scale is in hours 
( h )  and the length scale is in millimeters (mm). We used the values shown in Table 4.1 for 
our constants. 
Table 4.1 Parameters and Biological Constants 
rj eqn D,, = 3.() :< ai = O.lftM 12 = l.O;tM (1 0 
COllt. ft, = lO.O^tAf h. = l.0;iM 77 = l.O 
V eqn A, = ft = 0.007/iA/"' Vo = lO-'/tM Ao = I 
cont. iT[ = o.n 
c e.fjn Ai = 7.ro;<Ar'/»-' fi = 0.007/uVr"' /{ = 0.0 or 4.56/1"' 
/ eqn J = 0.222/1-' A2 = 19.0;tAr'/i-' t/j = l.28#t;Vf-' 
<i eqn A3 = l'l(5.0/^A'/-'/l-' f3 = o.oivw-' At = lO'VtA'f/i"' (Ti = 0.0 
t, P.qn A3 = l.|6.0/tAf-'/i-' f3 = O.Ol't/tW~' /<3 — 0.0 
Ca nqn fg = ITOO/tA/-' 
N eqn 0;v = 3.6 X lO-'mm'/i-' Tl = 1- at = O.l^iAf <12 = i.o^ivr 
cant. < = to" p 
0
 II 62 = I.OMW 72 = 1.0 
cont. A = t.l X 10""' m i  = 2  .'li = 44.13 =0.056/1"' 
cont. = O.OO5/1-' 0 = 0.3 A = 0.2MW C; = 10"V'Vf 
V eqn Dv — 3.6 X (Ti = 0.0 At = 73.0/nAf"'/i-' ft = 0.007/iW' 
cont. 'Pi = 2.0 = 2.0 '^'o = m.OfiM « =0.55 
cont. p = LO a = 0.495 b = 0.505 
C eqn Dc =3.6 X /i = 0.0 or 4.56/1"' At = 73.0M-'/»"' 1/1 — O.QO~fiM~^ 
cont. 03 = 2.0 0(3 = 2.0 
F eqn DF = 3.6 X 10-®mm^,'i-' 0 = O.222/1-' A, = l9.0#tjV/-'h-' 1/2 = 1.28/tiVf"' 
cant. 1^., = 1.0 A3 = 0.2 
A eqn 0,1 =6..5 X a-2 = 0.0 h = O-OUiM t/3 = 0.014/iA'r' 
cont. 'jij = 20.0 02 — 2.0 
la eqn A3 = l46.0/tW-i/i-' 1/3 = 0.014^ iVf~^  = 0.0 
Ca eqn = l700/</V/~' 
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CONCLUSIONS AND SUMMARY 
5.1 Conclusions 
In this thesis, we have developed a coupled system of partial differential equations which 
model the onset of vascularization. The system consists of two subsystems of partial differential 
equations, one of which is dependent upon two space and one time variable while the other 
is dependent upon one space and one time variable. They are coupled in such a way that 
solutions of the latter can be thought of as being a dynamical boundary condition for the 
former. This means that there is a separate mechanism for generating the boundary values for 
the concentrations of EC's and angiogenic factors in the ECM. This created some challenging 
computational problems. 
Moreover, we have obtained quite a good qualitative description of capillary branching 
from a given capillary. We have also obtained a good qualitative result in the angiostatin case. 
This illustrates mathematically one of the ideas of Dr. Folkman. 
Given the geometry of the dish and the concentration of growth factor, it should be possible 
to observe a forming trail of EC's moving under the matrigel from the EC side to the tumor 
side of the dish. 
We are hopeful that this model will be predictive rather than descriptive since we have 
mostly used experimental data. 
In his vascularization of tumors experiment, Folkman (1976) [14] indicated that a '^umor 
implanted in cornea of a rabbit grows slowly as a thin plate during the avascular phase (1). 
After a week or so, in response to the tumor angiogenic factor, capillaries begin growing toward 
the tumor from the limbus of the cornea, which is some 2.5 millimeters away (2). Within two 
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LIMaUS capillaries 
Figure 5.1 Tumor implanted in cornea, [14]. 
or three weeks the capillaries penetrate the tumor, and it begins to grow rapidly in three 
dimensions (3)." (See Figure 5.1 taken from [14].). 
In his experiment, he took the distance from capillary to tumor to be ' l .omm = 2.5 x 
.\s we stated in section (4.3), in our computations we took this distance to be IT/xm. .A.s we 
stated in Chapter 6, in the m = 1 case, we had f = 1.79 hrs as the onset of capillary sprouting 
in our length scale. Therefore, if we had used his length scale, we would have gotten 
1.79 hrs - , 1.79 2.5 x lO^^m , , 
X 2 .0mm = x days « 10.9 days 
li/im hum 24 
as the onset of capillary sprouting. Similarly, as stated in Chapter 6, we found in the m = 1 
case that capillaries penetrated the tumor at t = 2.27 hrs. Again, in his scale by the above 
arithmetic, one gets t  = 13.9 days for capillaries to penetrate the tumor. 
In his experiment we mentioned above, he also indicated that "after a week small capillaries 
entered the cornea from the edge nearest the tumor implant and began growing toward it. 
Initially at a rate of .2 millimeter per day finally at a rate of up to 1 millimeter per day''. From 
our numerical simulations given in Chapter 6, specifically from Figure 6.1 and from Figure 
6.19, one can obtain the following average rate of growth of capillaries in the m = 1 case 
0.017/2 mm 24 hrs 
(2.12-1.79) hrs W 
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Similarly, for m = 3 case we obtained the rate of growth to be approximately 0.8 mm/day. See 
Table 5.1 for the daily rate of growth of capillaries. We have also calculated the average speed 
of tip proliferation of capillaries for m = 1 case as ECs move toward tumor. (See Table 5.2). 
Table 5.1 Daily Rate of Growth of Capillaries 
Folkman's experiment 0.2 - 1.0 mm/day 
Our numerical result for m=l case 0.6 mm/day 
Our numerical result for m=3 case 0.8 mm/day 
Table 5.2 Daily Average Speed of Tip Proliferation of Capillaries 
Distance between the capillary and the tip Daily average speed 
3.1184 f im 0.47 mm/day 
5.1189 iJ,m 0.6001 mm/day 
8.5299 f im 1,7760 mm/day 
15.09 nm 2.7381 mm/day 
5.2 Summary 
In this thesis we have described the essential features of angiogenesis not only in one 
dimension but also in two dimensions along with numerical simulations. We have modeled Che 
migration of ECs as a reinforced random walk. That is, the direction of EC movement depends 
on probability transition rates. ECs are more likely to move to places where fibronectin density 
is low [5] and to follow a trail consisting of TAF and enzyme they produce that in turn destroys 
fibonectin. 
We have incorporated this notion by transition probabilities which reinforce the walking. In 
our model these transition probabilities are given as a function of enzyme, which promotes ceil 
movement by degrading the ECM basement, and fibronectin, which enhances EC adhesion to 
collagen. The enzyme acts as a catalyst for the degradation of the capillary wall by Michaelis-
Menten kinetics. 
In [23], the authors noted that the larger the transition probability sensitivity factors are. 
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the more quickly they gather in the opening of the basal lamina which is created by the 
protease. Also, they remarked that the size of the opening in the basal lamina is dependent 
both on the gradient in growth factor along the capillary wall and on the mean concentration 
of growth factor along the capillary wall. 
Since in our two-dimensional equations we are using the one dimensional equations as our 
boundary conditions, the size of the channel in the ECM is determined by the size of the 
opening in the basal lamina. 
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6 
NUMERICAL SIMULATIONS 
In this chapter, we present numerical simulations for the solutions of the capillary equations 
and those of the ECM equations. The first five set of figures are the snapshots for EC concen­
tration, EC density, TAF concentration, enzyme concentration and fibronectin concentration, 
respectively in the absence of angiostatin for the m = 1 and Df = 0 case. In this case, the 
channel opening is about 17— 18^m at about t = 2.27 hrs. The proliferation of EC's is high at 
the tip all the way to tumor. Notice that by about t = 2.27 hrs, the enzyme has accumulated 
near the tumor, and T.A.F has been degraded by the enzyme. In Figure 6.2, we see that the 
proliferation of EC's, is high in the tip all the way to the tumor. Notice also that the tip moves 
faster as it gets close to the tumor. (See Table 5.2). .A.lso, Figure 6.6 indicates that when 
there is no angiostatin, the inhibitor concentration, the active enzyme concentration and the 
inactive enzyme concentration are all zero. 
In Figures 6.7 - 6.14, we present the effect of angiostatin on the EC proliferation and 
closing the fibronectin channel. We introduced angiostatin at i = 2.25 hrs with a dosage of 
1.0 X 10'^fiM. By that time, ECs have already penetrated the tumor. By the time t = 5.5 hrs, 
the fibronectin channel almost closes and EC proliferation has been cut down considerably. In 
this case both of the fibronectin and EC want to come to a constant solution as active enzyme 
gets smaller and goes to zero. 
In Figures 6.15 - 6.18, we present numerical simulations in the absence of angiostatin for 
the m = 1 and Dp ^ 0 case. In this case, we get similar results as the Figures 6.1, 6.3, 6.4 and 
6.5. Recall that Dp # 0 case is the motion by mean curvature. In this case, we took nonzero 
decay constant in the ct and Ct equations (See Table 4.1). By about t = 2.15 hrs, the ECs 
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reach to tumor and the enzyme has accumulated near the tumor. 
In Figures 6.19 - 6.20, we present numerical simulations in the presence of angiostatin for 
the m = 1 and r 0 case for the EC and for the fibronectin concentrations only. In this 
case, we get similar results as the Figures 6.7 and 6.10. The effect of angiostatin on the EC 
proliferation and on closing the fibronectin channel is clear. By the time t = 7.75 hrs, the 
fibronectin channel almost closes and EC proliferation has been cut down considerably. 
In Figures 6.21 - 6.24, we present numerical simulations in the absence of angiostatin for 
the m = 3 and Dp = 0 case. This is the porous medium case. In this case, the time that 
V{0,y,t) takes to reache the threshold VQ is much longer than the time that V'fOji/ji) takes 
to reache the threshold Vq in the m = 1 case, which is expected because of the finite speed 
of propagation. What is amazing is that the time from the onset of capillary sprouting until 
ECs reach the tumor in the m = 1 case and in the m = 3 case are almost the same. .-Vlso, in 
this case the channel opening is about 8 — at about t = 8.74 hrs. (See Figure 6.29). It is 
known that the average capillary diameter is about 6 -8^m. That is why we think the porous 
medium case is probably more realistic than the m = i case. 
In Figures 6.25 - 6.28, we present numerical simulations for the capillary equations in the 
absence of angiostatin for the m = 3 and Dp = 0 case. 
In Figure 6.29, we present a figure that shows the channel opening in the m = 3 and 
Dp = 0 case. 
In Figures 6.30 - 6.33, we present numerical simulations for the capillary equations in the 
absence of angiostatin for the m = 1 and Dp 0 case. 
In Figure 6.34, we present a figure that shows the channel opening in the m = 1 and 
Dp ^ 0 case. 
From Figure 6.29 and Figure 6.34 it is clear that the channel openning in the porous 
medium cause (m = 3) is narrower than m = 1 case. This is also clear from the comparison of 
Figure 6.28 and Figure 6.33. 
Finally, in Figure 6.35 we present a figure that shows the biphasic response function of EC's 
to TAF. This function is named G(Ca) in the theory and has been constructed from fitting a 
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curve to data in [41] by the least squares method. 
In the the porous medium case we do not give any result for the angiostatin case because 
the result will be very similar to those presented for the m = 1 case. 
For the following numerical simulations we took Dc = Dci = = 0. 
Remark : We also took V]r,(y) = 0 with Vr{x , y , t )  7= 0. The form of this function was as 
follows. Suppose we have two half circles both are centered at (1,1/2) with radii and S-i 
respectively. Let Sf = (x — 1)^ + (</ — 1/2)^, 0 < x,!/ < 1. Then, we set 
Vr{x . y , t )  =  < "0 
0 
l - e - '  
if <^1 < S2, 
if > 62 
where UQ, m are some positive constants and 1 — e~^  is the normalizing constant. In this case, 
we obtained similar results to those presented in the numerical simulations section. However, 
we will not present the numerical simulations in this case. 
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Figure 6.1 EC Concentration In the Absence of Angiostatin, m  =  l ,  D f  =  0  
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Figure 6.2 EC Density In the Absence of Angiostatin, m = 1, Dp = 0 
t = 0. b. t = 1.79 hrs . c. t = 2.12 hrs. d. t = 2.27 hrs. 
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Figure 6.3 TAF Concentration In the Absence of Angiostatin, m = 1, 
Dp = 0. a. t = 0. b. t = 1.79 hrs . c. t = 2.12 hrs. d. 
t = 2.27 hrs. 
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Figure 6.4 Enzyme Concentration In the Absence of Angiostatin, m = 1, 
Djr = 0. a. t = 0. b. « = 1.79 hrs . c. i = 2.12 hrs. d. t = 2.27 
hrs. 
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Figure 6.5 Fibronectin Concentration In the Absence of Angiostatin, m = 1, 
DF = 0. a. i = 0. b. t = L79 hrs . c. t = 2.12 hrs. d. t = 2.27 
hrs. 
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Figure 6.6 a. Angiostatin Concentration, m = 1, Dp = 0 . t = 2.27 hrs . b. 
Inhibitor Concentration In the Absence of Angiostatin, m = 1, 
Dp = 0. t = 2.27 hrs . c. Active Enzyme Concentration In 
the Absence of Angiostatin, m = 1, Dp = 0. t = 2.27 hrs. d. 
Inactive Enzyme Concentration In the Absence of Angiostatin, 
m = l,Vp = 0. t = 2.27 hrs. 
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Figure 6.7 EC Concentration In the Presence of Angiostatin, m = 1, 
Dp = 0. a. t = 2.3 hrs. h. t = 3.68 hrs . c. t = 4.56 hrs. 
d. t = 5.5 hrs. 
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Figure 6.8 TAF Concentration In the Presence of Angiostatin, m = 1, 
Dp = a. t = 2.3 hrs. b. t = 3.68 hrs . c. t = 4.56 hrs. 
d. i = 3.5 hrs. 
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Figure 6.9 Enzyme Concentration In the Presence of Angiostatin, m = 1, 
Dp = 0. a. « = 2.3 hrs. h. t = 3.68 hrs . c. t = 4.56 hrs. d. 
t = 5.5 hrs. 
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Figure 6.10 Fibronectin Concentration In the Presence of Angiostatin, 
m = 1, Df = 0. a. t = 2.3 hrs. h. t •= 3.68 hrs . c. i = 4.56 
hrs. d. t = .5.5 hrs. 
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Figure 6.11 Angiostatin Concentration, a. t = 2.3 hrs. b. t = 3.68 hrs . c. 
t = 4.56 hrs. d. t = 5.5 hrs. 
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Figure 6.12 Inhibitor Concentration In the Presence of Angiostatin, m = 1, 
Dp = 0. a. t =• 2.3 hrs. b, t = 3.68 hrs . c. t = 4.56 hrs. d. 
t — 5.5 hrs. 
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Figure 6.13 Active Enzyme Concentration In the Presence of Angiostatin, 
m = 1, Dp = 0. a. t = 2.3 hrs. h. t = 3.68 hrs . c. t = 4.56 
hrs. d. t = 5.5 hrs. 
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Figure 6.14 Inactive Enzyme Concentration In the Presence of Angiostatin, 
m = 1,Df = 0. a. t = 2.3 hrs. b. i = 3.68 hrs . c. t = 4.56 hrs. 
d. t = 5.5hrs. 
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Figure 6.15 EC Concentration In the Absence of Angiostatin, m = 1, 
Dp ^0. a. i = 0. b. i = 1.81 hrs. c. t = 1.96 hrs. d. 
t = 2,15 hrs. 
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Figure 6.16 TAF Concentration In the Absence of Angiostatin, m = 1, 
Df ^ 0. a. t = 0. b. t = 1.81 hrs. c. t = 1.96 hrs. d. 
t = 2.15 hrs. 
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Figure 6.17 Enzyme Concentration In the Absence of Angiostatin, m = 1, 
Dp 7^ 0. a. t = 0. h. t — 1.81 hrs. c. t = 1.96 hrs. d. 4 = 2.15 
hrs. 
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Figure 6.19 EC Concentration In tfie Presence of Angiostatin, m = 1, 
Djr ^ 0. a. t  =  2.21. b. t  = 2.37hrs. c .  t  =  4.5hrs. d. 
t  —  7.75hrs. 
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Figure 6.20 Fibronectin Concentration In the Presence of Angiostatin, 
m =  1,  D p  ^ 0.  a .  t  =  2.21 .  h .  t  =  2.37hrs. c .  t  =  4.5hrs. d. 
t  = 7.75hrs. 
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Figure 6.21 EC Concentration In the Absence of Angiostatin, m = 3, 
D p  = 0. a. t = 0. b. t = 8.37hrs. c .  t  =  8.6hrs. d .  t  =  8.74hrs. 
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Figure 6.22 TAF Concentration In the Absence of Angiostatin, m = 3, 
D p  =  0 .  t  =  0 .  h .  t  =  8.37hrs. c. t = 8.6hrs. d. t  = 8.74hrs. 
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Figure 6.23 Enzyme Concentration In the Absence of Angiostatin, m = 3, 
D p  = 0. a. t = 0. b. t = 8.37hrs. c .  t  =  8.6hrs. d. t = 8.74 
hrs. 
74 
. Tumor Side 
0.995 
X 0.5 
Tumor side ; 
0 0.2 0.4 0.6 0.8 1 
y Capillary side 
—5 5 5 1 S 
0 0.2 0.4 0.6 0.8 1 
y Capillary side 
Tumor side; Tumor side 
0 0.2 0.4 0.6 0.8 1 
y Capillary side 
Figure 6.24 Fibronectin Concentration In the 
0 0,2 0.4 0.6 0.8 1 
y Capillaty side 
Absence of Angiostatin, 
•  - — - - I  8.6 hrs. 
1.25 
- -t=0 
0 t=8.6hrs 
—1=8.74 hrs 
1.15 
551.05 
0.95 
0.9 0.1 0.2 0.3 0.6 0.7 0.8 0 0.4 0.5 
y 
Figure 6.25 EC Concentration at the Capillary In the Absence of Angio-
statin, m = 3, Dp = 0 . 
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Figure 6.26 TAF Concentration at the Capillary In the Absence of Angio-
statin, m = 3, D p  =  0 .  
( I  
0.035 
- - t = 0  
• t=8.37 hrs 
0 t=8.6hrs 
— t=8.74hrs . 0.03 
« 0.025 
(5 0.02 
g 0.015 
c 0.01 
0.005 
y 
Figure 6.27 Enzyme Concentration at the Capillary In the Absence of An-
giostatin, m = 3, Dp = 0. 
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Figure 6.28 Fibronectin Concentration at the Capillary In the Absence of 
Angiostatin, m = 3, Dp = 0 . 
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Figure 6.29 Channel Opening In the Absence of Angiostatin, m = 3, 
D p  = 0. 
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Figure 6.30 EC Concentration at the Capillary In the Absence of Angio-
statin, m = 1, Dp r 0-
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Figure 6.31 VEGF Concentration at tiie Capillary In the Absence of Angio-
statin, m = 1, D p  ^  0. 
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Figure 6.32 Enzyme Concentration at the Capillary In the Absence of An-
giostatin m = 1, ^ 0. 
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Figure 6.33 Fibronectin Concentration at the Capillary In the Absence of 
Angiostatin, m = 1, Dp ^  0. 
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Figure 6.34 F(0,y,t). Channel Opening In the Absence of Angiostatin, 
m = 1, Dp ^ 0. 
85 
u Q) 
X) 
E 3 
z 
0 
0 
c 
0) (0 
OS 
£ 
u 
c 
T3 
0 U. 
0.5-
0 0.1 0.2 0.8 0.3 0.4 0.5 0.7 0.9 0.6 
TAF 
Figure 6.35 Diphasic Response Function of ECs to TAF. [41]. 
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APPENDIX I 
NONDIMENSIONALIZATION OF THE MODEL USING LITERATURE VAL­
UES 
We nondimensionalize the model by making the following scaling : 
X  v  Length scaling : x  =  — ,  y = — where l i  is the distance between capillary and tumor and 
'1 h  
I2 is the length of capillary . 
Time scaling : i = ~ where r is some reference time for pattern formation. 
Scaling for the equation •qt : ^ where tiq as in section (3.3). 
V o  ' 2  
_  .  -  .  .  u  _  T  J ,  r v  Scalmg for the equation vt : v = —, ffi = , Ao = -40, = —, «cat — 
To ro To 
A'TO = —^ where tq as in section (3.3). 
ro 
Scaling for the equation c< : c = —, f L  =  f i r .  
To 
Scaling for the equation /< : / = -^, /3 = /3t/o%, A = T" j Q  r o  J o  
where /q is some reference dosage of fibronectin. 
fl . ^2'no''' - '0 ; •^1''' 
^2 = —— 
ao ^ao 
o 1. /• 1 . _ fl (^2'nof 'o ''' TA Scalmg for the equation Of : a = —, aj  • ^o = —t = 1 «cot ~ 
T
J ^ A  
k^^T, where as in section (3.3). 
'•ao 
•  I  1 /  c  Scaling for the equation ia, : ia = —i ^3 = MsT", i'e = —1 Ca = 
r ao To 
Scaling for the equation Nt: iV* = —. D^r, = , (i = 1,2), ^ A = Ar^'. Aa = 
V o '  I j  
Aaro, M2 = M2T, ^  =  V .  
V *• — Scaling for the equation V't : V = —, Dv, = —• (j = 1,2), V'l — —, K = 
To /; To 
ro " 
Scaling for the equation Ct : C = —, Dc, = —, {j =1,2) 
rn I.-J 
F CL{ •" - 6{ • Scaling for the equation : F  =  — .  d j  =  — ,  ^ ^ 4  =  ^ * 4 1  =  T f  ( '  —  1 ) 2 ) ,  D p  =  
/o ro /o 
f o B p ,  q  =  l i ,  p  =  l l -
Scaling for the equation Af : A = —, /a = ^, —, (j = 1,2). 
« fjj J I j  
3  
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Scaling for the equation /g, : la = l a  
ao 
After dropping the tildes for notational convenience, we have the following nondimensional 
system of equations. First, at the capillary we now have: 
where 
d r ]  
d i  
d v  
m  
d c  
¥ t  
d t  
d a  
I t  
d i a  
d t  
d y  
+ 0-lT7 + Ur(y,t) 
f 
^(1 - /)/i -
l^catav 
+ <T27? + ar(t/,t) 
- ( J ' Z i a  
V r { y , t )  =  A o H { V { 0 , y , t ) - V Q ) V t { 0 , y , t )  a n d  a r { y , t )  =  A i H ( t  -  t o ) .  
Second, in the ECM we now have 
d N  
d t  
d t  
d t  
d t  
d x  
+ 
d x  
(d„ ,  (X,  , ) N ±  In { f ^ ) )  + I In 
Q(A') 
d y  
N V  
^(i'c,(x.»)^(C"))+i;(Dc,(x,v)|;(C")) 
kY„,VN 
+ Ki: + V 
D F { x , y ) - ' ^ '  
- f i C  
F„F2 -2F^F,F,^ + F^F,^ 
pF2 + qF^ 
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d A  
d t  
+  a ^ N  +  a r { y ,  t ) H ( F  -  / j )  
dia fciijAA' 
d t  A'4 + A 
ktatAN 
KA + A 
- f j - z h  
along with 
so that 
C = Ca + Ct, Ci — ftlaCa. 
c.= ^ 
1 + Vela 
Also, the nondimensional coupling equations between the capillary and the ECM are as follows. 
( 0 , y , t ) +  a i V { 0 , y , t )  
i } 2 a { y , t )  =  +02^(0, y,0 
^3c(!/,0 = - (0, y, t) + asdO, y, t) 
N ( 0 , y , t )  =  r / ' V ( y ^ t } H ( f i -  f ( y , t } )  
for some positive constants ai, oji 03, r p ,  i p i ,  t b ^ .  V'3, /i-
Moreover, the nondimensional boundary conditions are as follows. 
At I = 0 : 
i^r(0,y, 0 = 0. 
At I = 1 : 
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d A ^  
dC^ 
•Dci(l,y)-^{l,y,0 = 0 
D F ^ i h y , t )  =  0 .  
for some nonnegative constant 0i. 
At y = 0,1: 
where 
dV"" dV^ 
D v 2 { x , Q ) - ^ { x , Q , t )  = Dvjtar, 
Dc, (x, 0) ^ (i, 0, t) = Dc, (1,1) 1,0 
^F-:r-(x, 0, t )  = Dp—(i, 1, <) 
a y  a y  
d  d A " ^  
D A , { x , 0 ) - ^ { x , Q , t )  =  D^j{i, l)-^(i, l,f) 
d y  \ T { C a ,  f )  
( h ± l Y  H C a J )  -  \ h  I  ' •  \a2+Ca/ \02 + // 
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APPENDIX II 
NONDIMENSIONALIZATION OF THE MODEL BY CONSTANT SOLU­
TIONS 
We nondimensionalize the model by making the following scaling : suppose that the con­
stant solutions for both of the capillary and the ECM equations are nonzero. 
X  V Length scaling : x  =  — ,  y = 7- where /j is the distance between capillary and tumor and 
li I2 
I2 is the length of capillary . 
Time scaling : i  =  — where r  is some reference time for pattern formation. 
Scaling for the equation r f t  : 17 = 
T J e  I 2  
Scaling for the equation Ut : u = —> ^\ = ^0 = ^0 = tT' = 
Te t)e Ve 
cat'rrQTIe j^V _ Jjti 33 Ju seCtioD (3.3). 
r}OVg Ve 
c 
Scaling for the equation ct : c = —, = /zr. 
Scaling for the equation ft : /=-r> ^ ^ ^ = Pi'foVe^ Kat = = 
h  J o  
-  f  
— f \  =  —  where f o  is some reference dosage of fibronectin. 
Ca. /e 
• .  O .  .  T  ^0 7 -^iT" 7 J ^  Scaling for the equation Oj : a  =  —, 0*2 = , to = —• ^1 = 1 = 
Ctg Q,^ T flg 
^eat'^'^ao^e^ where Tao as in section (3.3). 
Off 
o t . r i  • •  •  i ' e  •  C q  Scaling for the equation la, : lo = —, M3 = = —, Co = —• 
! 'oe Ce 
Scaling for the equation Nt: N = Dj\}, = , (j = 1,2), 6 = 9t,  A = Aj = 
iVe 
^ •^e AjCe, M2 = M27", V = -TT-, -^l = • 
Ae 170 
V D v r V ^ ' ^  - V'l Scaling for the equation Vt : V = —, Dy^ = , (j = 1,2), Vl — —, Fr = 
VrT 
K  '  
C DctC^~^ Scaling for the equation Ct : C = —,  Dc ,  =  ^  ,  [ j  = 1,2) 
Ce I j  
Scaling for the equation Ft: F = d,- = —, ^4 = ^ 4-^1 = "T' (* = 2), D p  = 
i'e Cat Je 
feDp.. q = ll p = ll. 
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DatA, m—1 
'I 
•.0 = 1,2). A - f2 Scaling for the equation At : A = —, /2 = —, Da, = 
Jt 
Scaling for the equation I at '• la = 
/a. 
After dropping the tildes for notational convenience, we have the following nondimensional 
system of equations. First, at the capillary we now have: 
dr] 
dt 
dv 
di 
dc 
dt 
dt 
da 
dt 
dig 
It 
iVT] 
n + V 
+ aiT] + Vriy,t) 
Kl + v - f l C  
'^cat I 3 { l - z f ) f r i - - ^ f c a  
* J 
+a27y + ar(t/.<) 
A'4+a 
- Ml'a A'4 + a 
where 
V r{ y , t )  =  A o H { V { Q , y , t ) - V Q ) V t { Q , y , t )  a n d  a r ( y . t )  =  A i H { t  -  t o ) .  
Second, in the ECM we now have the following equations: 
(X, +1; (f-V. (X. y)'-^ry 
NG'{Ca)Co 
m 
dt F) 
+ e N { \  -  z : N )  +  H [ C a - C l ) - ^ L 2 N  
dt 
dt 
dt 
1 + G{Ca) 
A(Dv,(x.„)A,y™)) + |;(Dv,(x,„)|(K")) 
k^ NV 
-l^^'rC,N + Vr{x,y,t) (m>l) 
•"m + ^ 
A (dc, (X, „) ±(C")) + |(DC, (X. „)|;(C-)) 
kLVN 
Q { I < )  
+ - fiC 
.F,.F^~2FrFyF^ + F^Fyy 
iJF[x,y) 2-
pF^ + qF^ 
k^ FC 
^ ^ { l - z F ) F - - 0 ^  
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k-^ AM 
• ^ a 2 N ^ a , { y , t ) H { F - h )  
dia ki,AN 
dt A-4 + A 
KA + A 
f^Z^a 
along with 
so that 
C = Ca.-\- Ci, Ci = t/glaCa 
Ca= ^ 
1 + Uela 
Also, the nondimensional coupling equations between the capillary and the ECM are as follows. 
(0,y.t) + aiV(0, y.t) 
tb^aiyA) = y, t) + a2A(0, y. t) 
<^3c(y.t) = -^^^^J^^(0,y,O + c^3C(0,y.O 
j V ( 0 , y J )  =  i ) r i { y , t ) H { f x -  j { y A ) )  
for some positive constants ai, 02, Q3, P i ,  02> i'3-. fi-
Moreover, the nondimensional boundary conditions are as follows. 
At X = 0 : 
^r(Ot Vi = 0-
At I = 1 : 
(1, y)N-^ In ( ) = -diN 
T  d x  \ T i C a , F ) J  
V dV 
- ^ k D v A i , y ) - ^ { h y , t )  =  V L { y )  
93 
Z}A.(i,y)^(i,y,f) = 0 
D c , { i . y ) ^ [ i . . y . t )  =  Q  
D F ^ { h y , t )  =  Q .  
for some nonnegative constant 6i. 
At y = 0,1 : 
where 
r. , . . r d  ,  f  N  D N j { x , y ) N - ^  In I 
d y  \ f i C a , F )  
dV^ dV^ 
Dvj (x, 0)0,0 = Dv'j(x, 1)0 
n r. . ..amC" 
-j^(x,0,() = Oc,(x.l)-5^ Z?C2(X,0)^—(x,0,i Z?C2(X,1 —57—(x, 1,«) 
Dp|(x,0,.) = Drf(x,l,i) 
d 4"" dA  ^
Z?^j(x,0)-^(x.0,i:) = AajCx, l)-^(x,l.i) 
d y  \ T - { C a J )  
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APPENDIX III 
COMPUTER CODES 
function y=ksil(n,c) '/, the function used in the discretization of dN/dt 
gammalsl.O; al=.l: a2=1.0; '/, constants in \tau_l(c_a) 
y=ganunal»(a2-al) .•n./((c+al) .*(c+a2)); 
function y=ksi2(n,f) '/. the function used in the discietization of dN/dt 
gainina2=l.0; bl=10.00: b2=1.00; '/, constants in \tau_2(f) 
y=gainma2*(b2-bl) .*n. /((f+bl) .•(f+b2)); 
function y=V_L(x) 7iThe function used in B.C at x=l for V(x,y,t) 
s=12.7; */, normalizing constant 
K=l; 7. dosage 
m=5: 
y=s*K»(l-cos(200»pi»(x-0.495))) ."m.*(l-C(0<=x & x<0.495) + (0.505<x & x<=l))); 
function z = V_r(x,y,t) 7. Source function in dV/dt 
z=0»((0<=x' ft x'<=l)*(0<=y ft y<= 1)); 
function y=D_eta(x) '/, Diffusion function for \eta(y,t) 
y=0.000018; 
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function z=D_Nl(x,y) 7, Diffusion function for N(x,y,t) in x direction 
z=0.0006; 
function z=D_N2(x,y) 7. Diffusion function for N(x,y,t) in y direction 
2=0.000018; 
function z=D_Vl(x,y) 7. Diffusion function for V(x,y,t) in x direction 
2=0.06; 
function z=D_V2(x,y) 7. Diffusion function for V(x,y,t) in y direction 
2=0.001; 
function z=D_Cl(x,y) 7. Diffusion function for C(x,y,t) in x direction 
z=0; 
function z=D_C2(x,y) 7, Diffusion function for C(x,y,t) in y direction 
z=0: 
function z=D_F(x,y) 7. Diffusion function for F(x,y,t) 
7.z=0.000001; 
z=0: 
fxmction z=D_Al(x,y) % Diffusion function for A(x,y,t) in x direction 
z=l.1; 
function z=D_A2(x,y) X Diffusion function for A(x,y,t) in y direction 
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z=0.03; 
function y=KCx) 7, Heavyside fiinction 
7. y=(l-(( x<0.0))): 
a=le-22; 
y=l/2*(l+2/pi'*atan(x/a)); 7. continous form of Heavyside function 
function g=discretization(t,y) 
global N H cl fl  f2 vu_e alphal c2 alpha2 c3 dx dy theta lambda SI mu2 m ml 
global alphas c4 thetal 
7.This is the discretization of ECM and capillary equations in 
7,space variables .This dicretization has been done by using 
7.'Method of Lines' so that we have a very large system of ODE's 
7ito solve at each time step. 
7. 
7.This computer program has been done by SERDAL PAMUK.a 
/ .graduate student at Iowa State University .during fall 
/.semester of 1998. 
7. 
7.The number of ODE's to be solved at each time step is 
7.(6»N+10)*(M+1) where N is the number of grid points in 
7.x-direction and M is the number of grid points in y-direction 
g=Z6ros((6»N+10)«(M+l),  1); 7. size of function. 
yl=zeros((6»N+12)*(M+l), 1); 7. We define this vector to write everything in 
7. matrix notation. 
cl=0.3:7. the constant in N(0,y,t), namely psi. 
c2=2;7. the constant in V(0,y,t), namely psi_l. 
c3=100;7. the constant in A(0,y,t), namely psi_2. 
c4=2; 7. the constant in CCO.y.t), namely psi_3. 
dx=l/N,-7. step size in x direction. 
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dy=l/M;y, step size in y direction. 
vu_e=10000; */ the constant in c_a. 
alphal=2: '/, the constant in V(0,y,t). 
alpha2=2; '/, the constant in A(0,y,t). 
alpha3=2: 7, the constant in C(0,y,t). 
fl=.2: '/, threshold constant in N(0,y,t). 
f2=.05; 7, threshold constant in A_t(x,y,t). 
V0=0.0000001; 7, threshold constant in v_r(y,t). 
al=l/C2»dx"2); 7, some constauit used in the code. 
bl=l/(2*dy"2); % some constant used in the code. 
31=0.0001; 7. the threshold constant in the proliferation term 
m=l; 7f exponent in the porous medium equations. 
ml=2; 7. the power in the proliferation term. 
A_2=44.137. a constant in the proliferation term. 
A= 0.8; 7i the constant in front of v_r(y,t). 
M_V =165000; t  the molecular weight of VEGF in dalton. 
lambda=30.5/(M_V)"ml; 7. a constant in the proliferation term. 
theta=0.0028; the birth of ECs .  
thetal= 0»dx»0.017; 7i absorbing constant 
mu2=0.00025; 7. the death of ECs .  
sigmal=0.0; *1, the constant in front of \eta in dv(y,t)/dt. 
sigma2=0.0; 7, the constant in front of \eta in da(y,t)/dt. 
mu3=0.0; % inhibitor decay constant. 
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lamb<ial=3.65; 7, the constant in the numerator of dv(y,t)/dt. 
vul=0.007; 7, the constant in the denominator of dv(y,t)/dt. 
mu=0; 7. ezyme decay constant. 
beta=0.01; 7. f ibronection production constant. 
R=0.95: 7. the constant in the numerator of fibronectin decay term. 
S=1.28; 7i the constant in the denominator of fibronectin decay term. 
Iambda2=2»lambdal: 7. the constant in the numerator of da(y.t)/dt. 
vu2=2»vul; 7. the constant in the denominator of da(y,t)/dt. 
epsilon=10"(0.02); 7, the constant in the proliferation term 
11=0.017;7. the distance between tumor and capillary in mm. 
12=0.1;7. the length of capillary in mm. 
L13=0.7: 7. L13=(12'"4/ll"2)"(l/3) 7. scaling constant in curvature 
L14=0.02:X L14=(ll'"4/12"2)"(l/3) 7. scaling constant in curvature 
7. 
7. Main program begins 
y=y'; yl=yl'; 7. we take the transpose to fit the dimensions of vectors. 
ylCM+2:(2»N+l)#(M+l))=y(l:2»N*(H+l)); 
yl(2»(N+l)#(M+l)+l:(6*K+12)#(M+l))=y(2»N»(M+l)+l:(6#N+10)»(M+l)): 
7« To write the imlmowns in matrix notations. 
for i=l:N+l; 
Nl(i,  :)=yl((M+l)»(i-l)+l:i»(M+l)): 7. N(x,y,t) in matrix notation. 
V(i, :)=yl((N+i)#(M*l)+l: (N+l+i)»(M+l)) ;7. V(x,y,t) in matrix notation. 
C(i, :)=yl((2»N+l+i)«(H+l)+l:C2#N+2+i)*(M+l)) ;7t C(x,y,t) in matrix notation. 
F(i, :)=yl((3'»N+2+i)»(M+l)+l: (3*N+3+i)*(M+l)) :7. F(x,y,t) in matrix notation. 
Al(i,  :)=yl((4*N+9+i)»(M+l)+l: (4#N+10+i)»(M+l)) ;7i A(x,y,t) in matrix notation. 
I_a(i,:)=yl((5»N+10+i)»(K+l)+l:(5»N+ll+i)»(M+i));7.I_a(x,y,t) in matrix notation 
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end 
C_a=C./(l+vu_e»I_a); '/, construct C_a. 
eta=yl((4»N+4)*(M+l)+l: (4*N+5)#(M+1)); '/, \eta(y,t) 
v=yl((4*N+5)»(M+l)+l:(4»N+6)»(M+l)); 7. v(y,t) 
c=yl((4*N+6)*(M+l)+l:(4*N+7)*(M+l)); 7. cCy.t) 
f=yl((4*N+7)*(M+l)+l:(4#N+8)»(M+l)): 7. fCy.t) 
a_l=yl((4*N+8)*(H+l)+l:(4»N+9)*(H+l)); 7. a(y,t) 
i.a=yl ( (4*N+9) * (M+1)+1: (4»N+10)« (M+1)); 7. i_a(y, t) 
c_a=c./(l+vu_e»i_a); 7. construct c_a. 
7. Boundary conditions begins 
Nl(l,l:M+l)=cl*eta(l:M+l).*H(fl-f(l:M+l)); 
Nl(l:N+l,M+l)=Nl(l:N+l.H) + (ksil(Nl(l:N+l.M),C_a(l:N+1,M))).*..  .  
(C.a(l:N+l,H+l)-C.a(l:N+l.M)) + (ksi2(Nl(l:N+l,M),F(1:N+1,M))).*. .  .  
(F(1:N+1,M+1)-F(1:N+1,M)); 
Nl(l:N+l,l)=Nl(l:N+l,2) + (ksil(Nl(l:N+l,l),C_a(l:N+l,l)))•*• • • 
(C.a(l:N+l,l)-C_a(l:N+l,2)) + (ksi2(Nl(l:N+l,l),F(l:N+1,1))). *.. .  
(F(1:N+1,1)-F(1:N+1,2)); 
V(1:N+1,M+1)=V(1:N+1,M); 
V(1:N+1.1)=V(1:N+1,2); 
C(1:N+1,M+1)=C(1:N+1,M); 
C(1:N+1,1)=C(1:N+1,2): 
C(N+1,1:H+1)=C(N,1:M+1); 
F(1:N+1,M+1)=F(1:N+1,M); 
F(1:N+1,1)=F(1:N+1.2); 
F(N+1,1:M+1)=F(N,1:M+1); 
F(l,l:M+l)=F(2,l:M+l)j 
A1(1:N+1.H+1)=A1(1:N+1,M); 
Al(l:N+l,l)«Al(l:N+l,2); 
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A1(N+1,1:M+1)=A1(N,1:M+1); 
1=1:M+1: 
V(N+l.l:H+l)=(ll*dx./D.V(l. a -l)»dy))' .•V_L((l-l)#dy)+V(N.l:M+l); 
eta(M+l)=etaCH)+(ksil(eta(M),c_a(H))). 
(c.a(M+l)-c_a(M))+(ksi2(eta(M),f(H))).•(fCM+l)-f(M)); 
eta(l)=eta(2)+(ksil(eta(l),c_a(l))). 
(c.a(l)-c_a(2))+(ksi2(eta(l),f(1))).*(f(l)-f(2)); 
j=l:M+l; 
V(l,j)=l./(Il*alphal+D_v2(0,(j-l)#dy).»H(D_v2(0,(j-l)»dy))/dx). 
(Il*c2*v(j)+D_v2(0 ,(j-I)*dy).•H(D.v2(0.(j-l)*dy))/dx.*V(2.j)•"a); 
Al(l,j)=l./(ll*alpha2+D_A(0,(j-l)*dy).•H(D_A(0.(j-l)*dy))/dx) 
(Il*c3*a_l(j)+D_A(0, (j-l)»dy) .*H(D_A(0, (j-l)»dy))/dx.'»Al(2, j) ."m); 
C(l,j)=l./(ll*alpha3+D_C(0,(j-l)*dy).»H(D.C(0.(j-l)*dy))/dx).«...  
(ll*c4»c(j)+D_C(0,(j-l)*dy).»H(D_C(0,(j-l)»dy))/dx.*C(2,j).*m); 
Nl(N+l,j)=Nl(N,j)+(ksil(Nl(N,j).C.a(N,j))).*(C.a(N+l,j)-C_a(N,j))+...  
(ksi2(Nl(N,j).F(N,j))).»(F(N+1,j)-F(N,j))-thetal»Nl(N,j); 
'/. Boundary conditions ends. 
B=zeros(N+l,M+l); 
U=zeros(N+l,M+l); 
i=2:N;j=2:M: 
'/, Curvature for level line 
B(2:N,2:H)=((L13*(F(i+l,j)-F(i-l,j)).-2/(4#dx-2)+. 
L14*(F(i,j+l)-F(i,3-l))•"2/C4*dy-2))).-(3/2); 
B1(2:N.2:M)=B(2:N,2:M) .-(2/3): '/. gradient matrix 
U(2:N,2:H)=((F(i+l,j)-2*F(i.j)+F(i-l.j))/(dx-2).*. 
(F(i,j+l)-F(i.j-l))-^2/(4»dy-2)+...  
(F(i.j+l)-2*F(i.j)+F(i,j-l))/(dy-2)..  
(F(i+l.j)-F(i-l,j)).'2/(4*dx-2)-.. .  
'/, The 3/2 power of 
7, gradient matrix 
7, Numerator of curvatue 
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2 * ( F ( i + l . j ) ) / ( 2 * d x ) . * ( F ( i . j + l ) - F ( i , j - l ) ) / ( 2 * d y ) .  
(F(i+l,j+l)-FCi-l,j+l)-F(i+l.j-l)+FCi-l.j-3-))/C4*dx*dy)): 
for i=l:N+l 
for j=l:M+l 
if BCi.j) <=2.95*16-8. 
Z2(i.j)=0; 
else 
Z2(i.j)=U(i.j)./B(i.j): 
end 
end 
end 
'/, Boundary conditions ends. 
for j=l:M+l 
for i=l:N+l 
if ( VCi.j) < 0 I V(i.j)==0 ) 
P(i,j)=0; 
else 
P(i, j)=V(i,j) ."m; 7, The matrix V"ra 
end 
end 
end 
for j=l:M+l 
for i=l:N+l 
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i f  (  A l ( i , j )  < 0  I  A l ( i , j ) = = 0  )  
Q(i.j)=0: 
else 
Q(i,j)=Al(i,j) ."m; '/, The matrix Al'ro 
end 
end 
end 
for j=l:M+l 
for i=l:N+l 
if ( C(i,j) < 0 I C(i,j)==0 ) 
D(i,j)=0; 
else 
D(i,j)=C(i,j) ."m; '/, The matrix Cm 
end 
end 
end 
7, Discretization of dN/dt begins 
i=2:N:j=2:M: 
Xl=al*D_Nl((i-l)»dx,(j-l)*dy).»(2*Nl(i-l,j)-4*Nl(i,j)+2*Nl(i+l,j)-.. .  
(ksilCNKi, j) ,C_a(i,j)) + . . .  
ksiKNKi+1, j) ,C_a(i+l, j))) .*(C_a(i+l, j)-C_a(i, j)) + . .  . 
(ksiKNKi, j) ,C_a(i, j)) + . . .  
ksiKNKi-l,j) ,C.aCi-l,j))) .»CC_a(i, j)-C_a(i-l,  j))-. . .  
(ksi2(NKi, j) ,F(i, j)) + . . .  
ksi2(NlCi+l,j),FCi+l,j))) .•(FCi+l,j)-F(i,j)) + . . .  
(ksi2(NKi, j) ,F(i, j)) + . . .  
ksi2(NKi-l.j) .F(i-l,j))) .»(F(i.j)-F(i-l,j)))+...  
bl*D_N2((i-l)#dx, (j-D^dy) .•(2#Nl(i, j-l)-4»Nl(i, j)+2#NKi, j+1)-.. .  
(ksiKNKi, j) ,C.a(i,j))+...  
ksiKNKi, j+1) ,C_a(i, j+1))) .•(C_a(i,j+1)-C_a(i,j)) + . . .  
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(ksilCNlCi, j) .C_a(i, j))"'"- • • 
ksilCNKi, j-1) ,C_a(i,j-l))) .*(C_a(i, j)-C_a(i, j-1))-. . .  
(ksi2(Nl(i,j),F(i,j))+...  
ksi2(Nl(i,j+1) ,F(i,j+1))).*(F(i,j+l)-F(i,j)) + . . .  
Cksi2(Nl(i,j) ,F(i,j)) + . . .  
ksi2CNl(i,j-l).F(i,j-l)))•*CF(i.j)-FCi.j-l)))+••• 
a l / 2 » ( N l ( i + l , j ) - N l ( i - l . j ) - k s i l ( N l ( i ,  j )  , C _ a ( i . j ) ) . .  
(C_a(i+1,j)-C_a(i-l,j))"-•• 
k s i 2 ( N l ( i , j )  . F ( i . j ) ) • • C F C i + 1 . j ) ) ) • * • • •  
(D_NlCi*dx, (j-l)*dy)-D_Nl((i-2)»<ix, (j-l)*dy))+...  
bl/2*(NlCi,j + l)-Nl(i,j-l)"ksil(Nl(i,j),C_a(i,j)). . .  
(C_a(i,j+l)-C_a(i,j-l))-. . .  
k s i 2 ( N l ( i , j )  , F ( i , j ) ) . * ( F ( i , j + l ) - F ( i , j - 1 ) ) ) .  
(D_N2(Ci-l)*dx,j»dy)-D.N2((i-l)*dx,(j-2)^dy))+...  
(-mu2»Nl(i,j) + . . .  
(theta»Nl(i,j).»(1-Nl(i,j))+NlCi.j) .  
A2.*exp(-lambda»(C_a(i,j))."ml).»(l-2*lainbda#C_aCi,j)."2).»...  
((lainbdal*V(i,j).*Nl(i,j)./(l+vul*V(i,j)).»(l+vu_e*I_a(i,j))"-•• 
vu_e»lambda2»Al(i,j).»Nl(i,j)./(l+vu2*Al(i,j)).»C(i,j))./ . . .  
(l+vu_e»I_aCi, j))."2)).*H(C_a(i,j)-Sl)./ . . .  
(l+A2*C_a(i, j) .•exp(-lambda*(C_a(i,j))."ml)))..  
max(Z2(2:N,2:M).0)./sqrt(l+epsilon-2*Z2(2:N,2:H).*2); 
'/, Discretization of dV/dt begins 
i=2:N;j=2:M; 
X2=-lainbda3»V(i,j).»Nl(i,j)./Cl+vuS^VCi,j))+D_Vl((i-l)*dx,(j-l)*dy).*...  
al*(P(i+l,j) -2»P(i, j)+PCi"l. j))'*'D_V2((i-l)»dx, (j-l)*dy) .»bl.«.. .  
(P(i,j+1) -2"t.P(i,j)+P(i.j-l))+al/2»(P(i+l,j)-P(i-l.j)) •*•• • 
(D_Vl(i»dx,Cj-l)»dy)-D_Vl((i-2)*dx,(j-l)*dy))+...  
bl/2»(P(i,j+l)-PCi,j"l)).»(D_V2(Ci-l)»dx.j»dy)-.. .  
D_V2C(i-l)»dx,(j-2)»dy))+sigma3»Nl(i,j)+V_r(t,(i-l)»dx,(j-l)»dy); 
'/, Discretization of dv/dt begins 
W=[X2(1,1) X2(1.1:H-1) X2(1,M-1)]; 
j=l:M+l; 
X6=-lambdal*v(j). »eta( j).  /(l+\rul«v( j)) +sigmal*eta( j ) +.. .  
A»H(V(l,j)-VO).»H(l.j); 
104 
'/, Discretization of dc/dt begins 
X7=l2unbdal»v(j) .»eta(j) ./(l+vul*v(j))-mu*c(j) ; 
'/, Discretization of df/dt begins 
X8=beta»(l-f(j)).*f(j).*eta(j)-R./(l+S*f(j)).*f(j).»c_a(j); 
'/, Discretization of da/dt begins 
j=l:H+l; 
Y3=-lainbda2»a_l (j).  »eta( j).  /(l+v\i2*a_l( j)) +signia2*eta( j) +a_r(t, (j-1)*dy); 
7, Discretization of dA/dt begins 
i=2:N;j=2:H: 
Yl=-lainbda4»Al(i,j).*Nl(i,j)./(l+vu4»Al(i,j))+...  
D_Al((i-l)»dx,(j-l)*dy).*al.»(Q(i+l,j)-.. .  
2»Q(i,j)+ Q(i-1,j))+D_A2((i-l)#dx,(j-l)*dy).*bl.*(Q(i,j+l)-.. .  
2 * Q ( i , j ) + Q ( i , j - l ) ) + a l / 2 * ( Q ( i + l , j ) - Q ( i - l , j ) ) . .  
(D_Al(i»dx,(j-l)*dy)-D_Al((i-2)»dx,(j-l)»dy))+bl/2»(Q(i,j + l)-Q(i,j-1)). 
(D_A2((i-l)*dx,j*dy)-D_A2((i-l)*dx,(j-2)*dy))+sigina4#Nl(i,j)+...  
a_r(t,(j-l)*dy).»H(F(i,j)-f2); 
'/, Discretization of dC/dt begins 
X3=lainbdal*V(i, j) .»Nl(i,  j) ./(l+vul»V(i, j)) + . . .  
D_Cl((i-l)»dx,(j-l)»dy).•al»(D(i+l,j) -2»D(i,j)+...  
D(i-1,j))+D_C2((i-l)*dx,(j-l)»dy).•bl.».. .  
( D ( i , j + 1 )  - 2 * D ( i , j ) + D ( i , j - l ) ) + a l / 2 * ( D ( i + l , j ) ) • • • • •  
(D_Cl(i^dx,Cj-l)*dy)-D_Cl((i-2)*dx,(j-l)»dy))+...  
bl/2»(D(i,j+l)-D(i,j-1)).•(D_C2((i-l)*dx,j*dy)-.. .  
D.C2((i-1)•dx,(j-2)»dy))-mu»C(i.j): 
i=2:N;j=2:M; 
'/, Discretization of dP/dt begins 
X4=-D.F((i-l)*dx.(j-l)»dy).»Z2(2:N.2:M).»Bl(i,j)+.•• 
beta»(l-F(i,j)).»F(i,j)"R-/Cl+S»F(i,j)).*F(i,j).•C_a(i,j); 
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i=l:N+l;j=l:M+l; 
7, Discretization of dl_a/dt begins 
Y2=lambda2»Al(i,j).*Ni(i,j)./(l+vu2»Al(i,j))-mu3*I_a(i,j); 
7, Discretization of d(eta)/dt begins 
j=2:M; 
X5=bl*D_eta((j-l)*dy).*(2»eta(j-l)-4*6ta(j)+2*eta(j+ l ) - . . .  
(ksil(eta(j),c_a(j))+... 
ksil(8ta(j+l),c_a(j+l))).*(c_a(j+l)-c_a(j))+...  
(ksil(eta(j),c_a(j))+...  
ksil(eta(j-l),c_a(j-l))).*(c_a(j)-c_a(j-l))-.. .  
(ksi2(eta(j),f(j))+ksi2(eta(j+l),f(j+1))).»(f(j+l)-f(j))+...  
(ksi2(eta(j),f(j))+ksi2(eta(j-l),f(j-1))).*(f(j)-f(j-1))); 
7. Discretization of di_a/dt begins 
j=l:H+l: 
Y4=lainbda2*a_l(j).*eta(j)./(l+vu2*a_l(j))-mu3»i_a; 
R0=[X5(1) ,X5,X5(M-1)] : 7. gives eta in vector form 
Rl=zeros(N,H+l); 
R1(1:N-1,2:M)=X1: 
R1=R1': 
R1=R1(:); 7. gives N(x,y,t) in vector form 
R2=zeros(N,M+l); 
R2(2:N,2:M)=X2; 
R2=R2'; 
R2=R2(:); 7. gives V(x,y,t) in vector form 
R3=zeros(N+l,M+l); 
R3(2:N,2:M)=Y1; 
R3=R3'; 
R3=R3(:); 7. gives A(x,y,t) in vector form 
R4=2eros(N+l,M+1); 
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R4(2:N,2:M)=X3; 
R4=R4': 
R4=R4(:); 7, gives C(x,y,t) in vector form 
R5=2erosCN+l,M+l); 
R5(2:N,2:M)=X4: 
R5=R5'; 
R5=R5(:): 
X3=X3';Y2=Y2'; 7. change the sizes of X3, X4, Y2 by taking transpose. 
g=[Rl:R2:R4;R5;R0';X6';X7':X8';Y3':Y4';R3;Y2(:)] ; 7. put everything in 
7. vector form. 
7.The following is a script file. One needs to run this program to get 
7.the solution. 
global N M time cl fl  f2 vu_e alphal c2 alpha2 c3 dx dy theta lambda SI 
global alpha3 c4 mu2 m ml 
N=input('please enter n\ainber of grid pts in x direction'): 
M=input('please enter number of grid pts in y direction'); 
time=input('please enter final time'); 
a. .l=zeros(l,W*(M+l)); 7,initial guess for N(x,y,t) 
a. .2=zeros(l,N*(M+l)); 7tinitial guess for VCx.y.t) 
a. .3=zerosCl,(N+l)»(M+l)) ; 7.initial guess for C(x,y,t) 
a. .4=ones(l,(N+1)#(M+1)) ; 7.initial guess for FCx.y.t) 
a. .5=ones(l,M+l); 7iinitial guess for etaCy.t) 
a. .6=zeros(l,M+1); 7tinitial guess for vCy.t) 
a. .7=zeros(l,M+l); 7i initial guess for cCy.t) 
a. .8=ones(l,M+l); 7. initial guess for f(y.t) 
a. .9=zeros(l,M+1); 7.initial guess for aCy.t) 
a. .10=zeros(l,M+l); 7.initial guess for i.a(y,t) 
a. .ll=zeros(l,(N+l)»(M+l)); 7. initial guess for A(x,y,t) 
a. .12=zeros(l,(N+1)*(M+1)); 7. initial guess for I_a(x,y,t) 
ygues=Ca_l a_2 a_3 a_4 a_5 a_6 a_7 a_8 a_9 a_10 a.ll  a_12 ]'7.initial condition 
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options=odeset('RelTol',le-2,'AbsTol',le-2,'Stats','on'): 
tspan=linspace(0,time,100) ; 
Ct,y]=ode23('discreti2ation',tspan,ygues,options); 7, call the ODE solver 
sol=y'; '/, testing tremspose to fit the size. 
B2=sol(: .length(tspan)): */, solution vector at the final time 
W1=B2(1:N*(M+1)): 
W2=B2(N*(M+1)+1:2*N»(M+1)) ; 
W3=B2(2»N» CM+1)+1:(3#N+1)•(M+1)); 
M4=B2((3*N+1)»(M+1)+1:(4»N+2)*(M+1)); 
K1=B2((4*N+2)#CM+1)+1:(4*N+3)»(M+1)); 
K2=B2((4»N+3)*(M+l)+l:(4•N+4)•(M+l)); 
K3=B2 ((4*N+4)»(M+1)+1:(4^N+5)»(M+1)); 
K4=B2((4»N+5)»(M+1)+1:(4»M+6)*(M+1)); 
K5=B2((4*N+6)*(M+1) + 1: (4»N+7)»(M+1)) ,• 
K6=B2((4*N+7)»(M+l)+l: (4»N+8)«(M+1)) ; 
W7=B2(C4«N+8)*(M+1)+1:(5»N+9)»(M+1)); 
W8=B2((5*N+9)»(M+1)+1:(6*N+10)»(M+1)); 
'/ .gives N(x,y,t) in vector form 
y,gives V(x,y,t)in vector form 
'/.gives C(x,y,t)in vector form 
'/.gives F(x,y,t)in vector form 
'/.gives eta(y,t) 
'/.gives v(y,t) 
'/.gives c(y,t) 
'/.gives f(y,t) 
'/.gives a(y,t) 
'/.gives i_a(y,t) 
'/.gives A(x,y,t)in vector form 
'/.gives I_a(x,y,t)in vector form 
for j=l:M+l 
W5(j)=cl»Kl(j)*H(fl-K4(j)); '/. N(0.y,t) 
end 
lt=l:M+l; 
W9=V.L(1/M»(k-1)) : '/. Vd.y.t) 
'/. Define the following vectors 
W10=[W5';W1]; H11=CW2:W9']; W12=W3; W13=W4; 
for i=l:N+l 
N_l(: ,i)=W10((M+l)»(i-l)+l:i«(M+l)) ; '/. N(x,y,t) in matrix notation. 
V_l(: ,i)=tfll((M+l)»(i-l)+l:i*(M+l)); '/. V(x,y,t) in matrix notation. 
C_l(: ,i)=H12((M+l)«(i-l)+l:i»(M+l)) ; '/. C(x,y,t) in matrix notation. 
F_l(: ,i)=W13((M+l)«(i-l)+l:i»(M+l)); X F(x,y,t) in matrix notation. 
Al(: ,i)=W7((M+l)»(i-l)+l:i»CM+l)); '/, A(x,y,t) in matrix notation. 
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I_a(: ,i)=H8((M+l)*(i-l)+l:i*(M+l)); 7, I_a(x,y,t) in matrix notation, 
end 
C_a=C_l./(l+VT:_e*I_a): 7. construct C_a. 
B=zeros(N+l,M+l); 7. the denominator of curvature 
U=zeros(N+l,M+i); 7. the numerator of curvature 
Nl=N.l;F=F.l'; 
i=2:N;j=2:M; 
B(2:N,2:M)=((L13»(F(i+l,j)-FCi-l,j))-"2/(4«dx-2)+...  
L14»(F(i, j+l)-F(i. j-D) •'2/(4*dy-2))) .-(3/2) ,• 
U(2:N,2:M)=(CF(i+l,j)-2*F(i,j)+F(i-l.j))/(<ix"2) 
(F(i.j+l)-F(i,j-l)).-2/(4«dy-2)+...  
( F ( i , j + l ) - 2 * F ( i , j ) + F ( i . j - l ) ) / ( d y - 2 ) . .  
(F(i+l,j)-F(i-l,j))-"2/(4»dx-2)-.. .  
2 » ( F ( i + l , j ) - F ( i - l , j ) ) / C 2 » d x ) . * ( F ( i , j + l ) - F ( i , j - l ) ) / ( 2 * d y ) . .  
CF(i+l,j+l)-F(i-l,j+l)-F(i+l,j-l)+F(i-l,j-l))/(4»dx»dy)); 
for i=l:N+l 
for j=l:M+l 
if B(i,j) <=2.95*le-9, 
Z2(i,j)=0: 
else 
Z 2 ( i , j ) = U ( i , j ) . / B ( i , j ) :  
end 
end 
end 
7, Boundary conditions 
N.1(M+1,:)=N_1(M,:); 
N.1(1,:)=N.1(2.:); 
V.1(M+1,:)=V.1CM,:); 
V.1(1.:)=V_1(2,:); 
AlCM+i,:)=Al(M,:): 
A1(1.:)=A1(2.:); 
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A1(:,N+1)=A1(:,N); 
C_1(M+1.:)=C.1(H,:): 
C_1(1,:)=C_1(2,:): 
C_1(:,N+1)=C.1(:,N); 
F.1(H+1,:)=F.1(M,:); 
F.1(1.:)=F.1(2,:): 
F_1(:.N+1)=F.1(:.N); 
F(:,1)=F(:.2); 
j=l:H+l: 
V.l(j.1)=1. /(alphal+D_V2(0,(j-1)«dy).*H(D.V2(0.(j-1)*dy))/dx).•.. .  
(c2»K2(j)+D_V2(0,(j-1)»dy).»H(D_V2(0,(j-1)*dy))/dx.•V.l(j,2)."m); 
C_l(j,l)=l./(alpha3+D_C(0,(j-l)*dy).*H(D_C(0,(j-l)*dy))/dx)..  
(c4»K3(j)+D_C(0,(j-l)*dy).*H(D_C(0,(j-l)»dy))/dx.*C(j,2)."m); 
A l C j , l ) = l . / ( a l p h a 2 + D _ A ( 0 , ( j - l ) * d y ) . • H C D _ A ( 0 , ( j - l ) * d y ) ) / d x ) .  
(c3#K5(j)+D_A(0,(j-l)*dy).#H(D.A(0,(j-l)»dy))/dx.»Al(j,2).-m): 
N.Kj ,N+l)=N_l(j ,N) + (ksil(N.l(j .N) ,C_a(j ,N))) .*(C_a(j ,N+1)-C.a(j ,N))+...  
(ksi2CNl(j,N),FCj.N)))>(F(j,N+l)-F(j,N))-thetal*N_l(j,N): 
V.l(j.N+l)=(ll*dx./D_V(l,(j-l)«dy)).*(V_L(l/M*(j-l)))'+V.l(j.N); 
Define the following vectors to scale the axis of graphs 
X=0:1/N:1; Y=0:1/M:1; 
[zl,z2]=meshgrid(Y(l:l:M+l),X(1:1:N+1)); 
y_l=zl';x_l=z2'; 
'/ .niesh(y_l,x_l,V_lCl:l:M+l,l:l:N+l)) ; 
mesh(y_l,x_l,N_l(l:l:M+l,1:1:N+1)); 
•/.mesh(y_l,x.l,C_l(l:l:M+l.l:l:N+l)); 
•/.mesh(y_l,x.l,F_1 (1:1 :M+1,1:1 :N+1)); 
*/iniesh(y_l,x_l,Al(l:l:M+l,l:l:N+l)); 
7jnesh(y.l,x.l,I_a(l:l:H+l,l:l:N+l)); 
Xmesh(y_l,x.l,C.a(l:l:M+l,l:l:N+l)); 
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r=[l 1 1]; */, some arbitrary vector 
view(r) Z adjust the view of the graph 
'/.xlabel('y') ;ylabel('x') izlabelCTumor growth factor') 
xlabel('y');ylabel('x');zlabeX('Endothelial cell density') 
'/.xlabelCy') lylabelCx') ;zlabel('Enz3nne concentration') 
'/.xlabelC'y') ;ylabelC'x') ;zlabel('Fibronectin concentration') 
•/.xlabel (' y'); ylabel (' x'); zlabel (' Angiostatin concentration') 
XxlabelC'y');ylabel('x') ;zlabel('Inhibitor concentration') 
'/.xlabelCy') lylabelCx') :zlabel('Active enzyme concentration') 
Ill 
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